

Anlotinib, a novel TKI, as a third-line or further-line treatment in patients with advanced non-small cell lung cancer in China A systemic review and meta-analysis of its efficacy and safety

Haiyong Ye, MS^a, Zhaoyi Li, MS^a, Kangning Liu, BS^a, Feng Zhang, MS^b, Zhengliang Cheng, MS^{c,*}

Abstract

Purpose: In this meta-analysis and systemic review, we focused on the effectiveness and safety of anlotinib in patients with advanced non-small cell lung cancer(NSCLC).

Methods: The databases of PubMed, EMBASE, Cochrane Library, CNKI, Wanfang, and CBM were searched by 2 investigators up to April 2020. Titles and abstracts of all records were screened and eligible publications were retrieved in full. Review Manager (version 5.2, Cochrane Library) was used for data analysis. The outcomes of interest were disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and treatment-related adverse event (TRAE). Data was pooled for quantitative analysis and the effect size was reported as hazard ratio for survival outcomes and odds ratio (OR) for safety outcomes, both with a random-effects model.

Results: A sum of 1480 patients were included in 11 trials ranging from 2018 to 2020. Substantial improvements of PFS, OS, and DCR were observed in patients treated with anlotinib alone or in combination with other conventional treatment. Accompanied TRAE included statistically significant higher risk for hypertension (OR = 11.05, 95% confidence interval [CI]=7.85–15.55, P<.001), hepatic dysfunction (OR=1.96, 95% CI=1.29–2.68, P<.001), diarrhea (OR=2.20, 95% CI=1.17–4.16, P<.05), and hemoptysis (OR=2.59, 95% CI=1.71–3.93, P<.01).

Conclusions: Our study suggested that anlotinib as maintenance therapy for advanced NSCLC patients is associated with prolonged PFS and OS as well as DCR improvement, but it was accompanied by increased risk of TRAE, such as hypertension, hepatic dysfunction, diarrhea and hemoptysis. Although much effort has been made to clinical trials of anlotinib, further studies are warranted to provide more convincing evidence.

Abbreviations: CI = confidence interval, DCR = disease control rate, LC = lung cancer, NSCLC = non-small cell lung cancer, OR = odds ratio, OS = overall survival, PFS = progression-free survival, RCTs = randomized controlled trials, TKIs = tyrosine kinase inhibitors, TRAE = treatment-related adverse event.

Keywords: advanced non-small cell lung cancer, anlotinib, systemic review and meta-analysis, TKI, tyrosine kinase inhibitors

Editor: Jianxun Ding.

HY, ZL, and KL contributed equally to this work.

The research was supported by 2020 National College Students' Innovation and Entrepreneurship Training Program (202010344006).

The authors have no conflicts of interests to disclose.

All data generated or analyzed during this study are included in this published article [and its supplementary information files]. Data sharing not applicable to this article as no datasets were generated or analyzed during the current study.

^a The First Clinical College of Zhejiang Chinese Medical University, Hangzhou, Zhejiang, ^b Anhui University of Chinese Medicine, Hefei, Anhui, ^c People's Hospital of Changxing, Huzhou, Zhejiang, China.

^{*} Correspondence: Zhengliang Cheng, People's Hospital of Changxing, Huzhou 313000, Zhejiang, China (e-mail: cz/1009215257@163.com).

Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal.

How to cite this article: Ye H, Li Z, Liu K, Zhang F, Cheng Z. Anlotinib, a novel TKI, as a third-line or further-line treatment in patients with advanced non-small cell lung cancer in China: a systemic review and meta-analysis of its efficacy and safety. Medicine 2021;100:23(e25709).

Received: 18 September 2020 / Received in final form: 10 February 2021 / Accepted: 9 April 2021

http://dx.doi.org/10.1097/MD.000000000025709

1. Introductions

Worldwide, lung cancer (LC) remains the top leading cause of cancer-related deaths with a 5-year survival rate of less than 20%.^[1,2] Non-small cell lung cancer (NSCLC), usually found to be at advanced stage when firstly diagnosed, constitutes the largest proportion of lung cancer cases (approximately 80%–85%).^[3] It was reported that LC patients with stage IV had a 1-year survival rate of just 15% to 19% compared with 81% to 85% for stage I.^[4] Data have shown that LC deaths in China, which accounts for one fifth of the world's population, are more than one third of the world total number of LC deaths.^[5,6]

Historically, the Food and Drug Administration approved standard regime for advanced NSCLC is platinum doublet chemotherapy.^[7] However, the choice of platinum-based doublet has generally been influenced by the histologic subtype.^[8] In recent years, immunotherapy combined with chemotherapy has been recommended as the first-line agent in metastatic LC. Researchers have certified that the combination of programmed cell death-1/programmed death ligand-1 inhibitors and chemotherapy as a promising therapeutic option for advanced NSCLC.^[9]

Accumulated evidences have confirmed that multi-target antiangiogenic-tyrosine kinase inhibitors (TKIs), one of the antiangiogenic agents, combined with chemotherapy, targeted therapy and immunotherapy can confer a significant overall survival (OS) benefit to NSCLC patients.^[10,11]

Anlotinib, as a novel TKI, has been approved by the China National Medical Products Administration for patients in China since 2018. According to data from clinical trials, anlotinib has brought a statistically and clinically significant improvement in survival among patients with advanced NSCLC who have progressed on at least 2 lines of prior systemic chemotherapies.^[12] Therefore, in this systemic review and meta-analysis, we focused on the effectiveness and safety of anlotinib on advanced NSCLC patients.

2. Materials and methods

2.1. Search strategy

Two authors searched PubMed, EMBASE, Cochrane Library, CNKI, Wanfang, and CBM databases (up to April 2020) without any language restrictions. Search terms included "Anlotinib," "AL-3818," "lung cancer," " lung carcinoma," "lung neoplasm," "NSCLC". In addition, we also checked each reference listed in the included studies, all related review and guidelines to include any previously ignored papers.

This systematic review has been registered in PROSPERO, the registration ID is CRD42020180480.

2.2. Participants 2.2.1. Inclusion criteria.

- 1. Age between 18 and 80 years old.
- 2. Randomized controlled trials (RCTs);
- 3. The study population consisted of patients with histologically or cytologically proved stage IIIB or IV NSCLC;
- 4. The study contained an intervention group: Anlotinib or in combination with other conventional treatment, and a control group: Placebo or other conventional treatment;
- 5. at least one of the following outcomes: disease control rate (DCR), progression-free survival (PFS), OS and treatment related adverse event (TRAE) were reported.

2.2.2. Exclusion criteria.

- 1. Age ≤ 18 or ≥ 80 years old.
- 2. not RCTs;
- 3. The patients in the study were not histologically or cytologically proved to be stage IIIB or IV NSCLC;
- 4. The intervention group was not anlotinib or combination of anlotinib and other conventional treatment;
- 5. incomplete outcomes were reported;
- 6. The number of patients in any arm was less than 15.

2.3. Outcome measures

The following outcomes were reported: DCR, PFS, OS and treatment-related toxicities (adverse event grade \geq 3, TRAEs).

2.4. Risk of bias assessment

Two authors assessed the risk of bias of each eligible study using the Cochrane risk of bias tool which was advised by the Cochrane Handbook as follows: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting and other bias. The judgment of each domain had 3 options (low risk, unclear risk, and high risk). Two authors independently assessed the risk of eligible studies. We solved all disagreements occurring in assessing the risk of each eligible study.

2.5. Study selection and data collection

Two authors independently searched the articles for inclusion, as described. Titles and abstracts of all records were screened and eligible publications were retrieved in full. Hand searching of reference lists of relevant studies and reviews was used to identify additional articles. Differences in judgment during the selection process were settled by discussion and consensus. The methodological quality of the studies was assessed independently by 2 authors using the Jadad scale, and the study quality was settled by consensus.

2.6. Quality assessment

Improved Jadad scale was applied to assess the quality of RCTs including randomization, blinding of participants, personnel, outcome assessors, incomplete outcome data, and other threats to validity.^[13] Four to 7 points represent for high quality, while 1 to 3 points for low quality.

2.7. Statistical analysis and data synthesis

Review Manager (version 5.2, Cochrane Library) was used for statistical analysis. Six researchers participated in this work: 2 conducted the data extraction independently, 2 conducted the data synthesis independently, and 2 carried out the data analysis to resolve any discrepancies, and ensure the accuracy of results. The heterogeneity of the included studies was analyzed by using I^2 , and if data shows high level of heterogeneity ($I^2 > 50\%$), subgroup analyses was performed to investigate the sources by age, the histological types, EGFR mutation or the side effects, etc. If more than ten articles were included, a meta-regression analysis was performed to further explore the potential effects of the heterogeneity and confounders on the outcomes.

2.8. Ethical approval and patient consent

The ethical approval and informed patient consent were stated explicitly in the part of study design and patients of the original articles of all the included studies.

3. Results

3.1. Description of studies

The flow diagram was depicted as in Figure 1. Totally, 233 studies were initially searched by strategy and hand from the above 6 electronic databases (Fig. 1). After removal of 88 duplicate studies, 145 articles were left for screening. After reviewing by the titles and abstracts, we excluded 69 studies, including 30 non-RCTs, 4 basic experiments, 24 reviews, and 11 irrelevant studies. We retrieved the full texts of 76 articles for further evaluations, of which 65 studies were excluded, including 6 irrelevant studies, 5 non-RCTs, 48 incomplete outcomes, 2 low quality and sample size of 1 arm ≤ 15 (n=4). In the end, a total of 11 articles were included for this review.^[14-25]



Figure 1. Guidelines flow diagram of the included studies.

3.2. Characteristics of included studies

As shown in Table 1, a total of 1,480 NSCLC patients were included from year 2018 to 2020 with 1 phase II studies and 3 phase III studies. The baseline characteristics of the included trials were comparable between the intervention groups with the comparator groups. As to the histology of NSCLC, 8 trials referred to the Adenocarcinoma, 5 referred to the squamous cell carcinoma while 5 referred to the other types.

The chemotherapy regimens included anlotinib (12 mg/d from day 1–14 for 21 d/cycle (n=7 trials); anlotinib plus pleural infusion chemotherapy with cisplatin (n=2 trials); radiotherapy plus anlotinib (n=1 trials); docetaxel 75 mg/m² for d1 plus anlotinib 12 mg/d from day 1 to 14 for 21 d/cycle (n=1 trials).

Table 1

Characteristics	of the	included	studies	of the	systematic	review
Gilaracteristics	or the	included	Sludies	or the	systematic	review.

First author	year	Size	phase	Histology	Interventions (regimen, participants)	Comparators (regimen, participants)	Main outcomes	Jadad score
Han ^[1]	2018	117	II	Adenocarcinoma $(n = 104)/SCC$ (n = 13)	anlotinib (12 mg per d, per os; d 1- 14; 21 days per cycle, n=60)	Placebo (n=57)	1234	7
Han ^[2]	2018	439	III	Adenocarcinoma $(n = 336)/SCC$ (n = 86)/others(n = 15)	anlotinib (12 mg per d, per os; d 1- 14; 21 d per cycle, n=296)	Placebo (n=143)	1234	7
Yue	2018	80	/	Adenocarcinoma $(n = 67)/O$ thers $(n = 13)$	Anlotinib + Pleural infusion chemotherapy with cisplatin (n = 40)	Pleural infusion chemotherapy with cisplatin $(n = 40)$	134	5
Zhou	2019	437	III	Adenocarcinoma (n $=$ 336)/SCC (n $=$ 86)/Others (n $=$ 15)	anlotinib (12 mg per d, per os; d 1- 14; 21 days per cycle, n=294)	Placebo (n=143)	1334	5
Cheng	2019	50	/	Adenocarcinoma $(n = 17)$ /Others $(n = 3)$	Anlotinib + Pleural infusion chemotherapy with cisplatin (n = 25)	Pleural infusion chemotherapy with cisplatin $(n=25)$	14	3
Dai	2019	40	/	Adenocarcinoma $(n=21)/SCC$ (n=19)	anlotinib (12 mg per d, per os; d 1- 14; 21 days per cycle, n=20)	Placebo (n=20)	1334	4
Yu	2019	66	/	Adenocarcinoma (n=66)	Docetaxel 75 mg/m ² ivgtt d1+ anlotinib 12 mg per d, per os; d 1-14; 21 d per cycle, (n=33)	Docetaxel 75 mg/m ² ivgtt d1, 21 days per cycle, (n=33)	14	2
Huang, Cai	2020	40	/	/	Radiotherapy+ anlotinib (12 mg per day, per os; d 1-14; 21 d per cycle, n=20)	Radiotherapy (n=20)	14	2
Jiang	2020	97	III	Adenocarcinoma (n = 86)/SCC (n = 8)/Others (n = 3)	anlotinib (12 mg per d, per os; d 1- 14; 21 d per cycle, n=67)	Placebo (n=30)	234	7
Huang, Li	2020	70	/		anlotinib (12 mg per d, per os; d 1- 14; 21 d per cycle, n=35)	Platinum-based chemotherapy regimen (12 mg per d, d 1– 14; 21 days per cycle, n= 35)	1334	3
Wang	2020	44	/	/	anlotinib (12 mg per d, per os; d 1- 14; 21 d per cycle, n=22)	Placebo (n=22)	234	4

① DCR = disease control rate, ③ PFS = progress free survival, ④ OS = overall survival, ④ AE = adverse events, SCC = squamous cell carcinoma.

Regarding the regimens of comparators, the placebo was used in 6 trials, pleural infusion chemotherapy with cisplatin was used in 2, radiotherapy was used in 1, docetaxel was used in 1, and platinum-based chemotherapy regimen was used in 1.

Additionally, it provided information of the outcomes data. For DCR outcomes, 9 trials reported; 7 trials reported PFS outcomes; 8 studies reported OS outcomes; besides, 11 studies reported the treatment related adverse events.

3.3. Risk of bias in individual study

Results of the risk of bias are showed in Figure 2A and Figure 2B.

3.3.1. Random sequence generation. All the studies were at low risk of bias for using a computer random number generator or random number table method.

3.3.2. Allocation concealment. Seven trials were analyzed to be at low risk of bias for reporting allocation concealment or the allocation method having no influence on the results. Four studies did not mention allocation concealment being judged to be at unclear risk of bias.

3.3.3. Blinding of participants and personnel. Nine trials set up placebo arm and reported blinding of patients and study personnel being judged to be at low risk of bias. Two studies were judged to be at unclear risk of bias for not mentioning it.

3.3.4. Blinding of outcome assessors. Eleven studies were judged to be at low risk of bias for setting up placebo arm or

blinding the data collectors or being analyzed to have little possible to break the blinding.

3.3.5. Incomplete outcome data. Patients in all the 11 studies were reported to complete the whole course of treatment being judged to be at low risk of bias.

3.3.6. Selective reporting. Ten trials were not registered anywhere and provided no information of the selective report, to be judged to be at unclear risk of bias while 1 remained to be unclear.

3.3.7. Other bias. Ten studies were judged to be at low risk of bias for being tested to be free of apparent other bias and 1 stayed unclear

3.4. PFS outcomes

An evident PFS improvement (mean difference = 2.36, 95% confidence interval [CI] = 1.64–3.08, P < .01 in Fig. 3A; hazard ratio = 0.25, 95% CI = 0.22–0.30, P < .01 in Fig. 3B) was observed in patients with anlotinib or combination of anlotinib and other conventional treatment, which significantly outperformed Placebo or other conventional treatment (Fig. 3). Notably, according to the result of the funnel plot in Figure 4 with a small degree of heterogeneity across the trials, a high quality of evidence and a strong recommendation were assigned to the pooled evidence of PFS.

3.5. OS outcomes

The regimen of anlotinib or combination of anlotinib and other conventional treatment for advanced NSCLC obviously led to a



Figure 2. (A): Risk of bias graph; (B): Risk of bias summary: review of authors assessment about each risk of bias item for each included study. "+": low risk of bias; "?": unclear risk of bias; "-": high risk of bias.



large improvement in OS (mean difference=3.14, 95% CI= 1.83-4.45, P < .001 in Fig. 5A; hazard ratio=0.70, 95% CI= 0.60-0.82, P < .001 in Fig. 5B) with slight heterogeneity across included trials (Fig. 6).

3.7. Treatment related adverse event (TRAE)

3.6. DCR outcomes

An apparent DCR improvement (odds ratio [OR]=6.50, 95% CI=4.90-8.62, P < .001) (Fig. 7) showed that the method of using anlotinib to implement advanced NSCLC appeared more effective. Furthermore, no significant heterogeneity was represented across included trials (Fig. 8).

Overall, treatment related adverse events were proved to be more frequent in the experimental group (OR = 1.97, 95% CI = 1.43–2.72, P < .001). Specifically, significantly higher risk of TRAE for hypertension (OR = 11.05, 95% CI = 7.85–15.55, P < .001), hepatic dysfunction (OR = 1.96, 95% CI = 1.29–2.68, P < .001), diarrhea (OR = 2.20, 95% CI = 1.17–4.16, P < .05), hemoptysis (OR = 2.59, 95% CI = 1.71–3.93, P < .01) in intervention arm (Fig. 9) were observed.

However, no statistical significance was detected of leukopenia (RR = 1.12, 95% CI=0.59-2.12, P=.72), nausea and vomiting (RR = 1.21, 95% CI=0.82-1.78, P=.34), pulmonary infection





(RR = 1.49, 95% CI = 0.79-2.8, P = .22), and dyspnea (RR = 1.41, 95% CI = 0.92-2.17, P = .12) between 2 groups(Fig. 9).

As was detected in the funnel plot of the comparison of TRAE, the use of anlotinib did not lead to significant heterogeneity across included trials (Fig. 10).

PFS, OS, DCR improvement in patients with anlotinib or combination of anlotinib and other conventional treatment.

Despite of apparent efficiency, higher risk of TRAE significantly increased for anlotinib arm, such as: hypertension, hepatic dysfunction, diarrhea and hemoptysis. However, the possibility of leukopenia, nausea and vomiting, pulmonary infection and dyspnea are comparable in 2 arms.

4. Discussion

4.1. Summary of main findings

In this article, the efficacy and safety of anlotinib as maintenance therapy for advanced NSCLC patients was analyzed and reported from 11 randomized controlled trials. Our results suggest evident

4.2. Applicability of the current evidence

This meta-analysis results will hopefully serve as useful feedback information for maintenance regimen of advanced NSCLC patients.



	Experim	ental	Contr	ol		Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% C	M-H, Random, 95% Cl
Cheng 2019	24	25	20	25	1.6%	6.00 [0.65, 55.66]	
Dai 2019	17	20	6	20	3.2%	13.22 [2.79, 62.67]	
Han(1) 2018	50	60	18	57	9.8%	10.83 [4.50, 26.10]	
Han(2) 2018	238	296	53	143	33.8%	6.97 [4.47, 10.87]	
Huang 2019	18	20	11	20	2.7%	7.36 [1.34, 40.55]	
Huang 2020	27	35	21	35	7.1%	2.25 [0.80, 6.36]	
Yu 2019	28	33	21	33	5.5%	3.20 [0.98, 10.49]	
Yue 2018	38	40	34	40	2.8%	3.35 [0.63, 17.74]	
Zhou 2019	238	294	53	143	33.4%	7.22 [4.62, 11.29]	
Total (95% CI)		823		516	100.0%	6.50 [4.90, 8.62]	•
Total events	678		237				
Heterogeneity: Tau ² =	0.01; Chi ²	= 8.41, 0	df = 8 (P =	= 0.39);	l² = 5%		
Test for overall effect:	Z = 13.00	(P < 0.00	0001)	,.			0.01 0.1 1 10 100 Favours [experimental] Favours [control] Favours [control] Favours [control]
Fig	ure 7. Fore	est plot o	of the con	npariso	n of diseas	se control rate between e	experimental group and control group.

Anlotinib is the first China National Medical Products Administration-approved drug for patients with advanced NSCLC following at least 2 lines of chemotherapy in China.^[12] Besides, single agent anlotinib has been approved by the China Food and Drug Administration as a third-line treatment for advanced NSCLC patients.^[26] According to research, anlotinib has demonstrated a clinically significant OS and PFS prolongation of advanced lung cancer patients.^[27] What is more, as an orally administered anti-angiogenesis inhibitor, anlotinib displayed manageable toxicity, long circulation, and broad-spectrum antitumor potential for advanced lung cancer patients with low KPS scores.^[28]

For anlotinib, hypertension is one of the independent protective factors. Research demonstrated that anlotinib, a potent multi-tyrosine kinases inhibitor (TKI), could suppress blood vessels sprout and micro vessel density by inhibiting on VEGF/PDGF-BB/FGF-2-induced angiogenesis, causing the risk of hypertension indirectly.^[29]

Diarrhea was reported as TRAE in many pre-approval clinical trials. An animal experiment suggested that the major absorption sites for oral anlotinib were probably the stomach and duodenum. Anlotinib, just as many other approved TKIs, demonstrated pH-dependent hydrophilicity and lipophilicity. While, in the jejunum and the ileum with pH 6.5, the aqueous solubility appeared to be too low to provide adequate absorption, thus causing the issue of diarrhea.^[30]

As is reported, hepatic dysfunction is one of the serious TRAE in clinical trials with TKIs. Mitochondrial dysfunction is regarded to play a central role in induction of hepatotoxicity. Research certified that the main mechanisms of drug-induced liver injury were based on the production of reactive metabolites generated by phase I oxidation reactions, immunological and/or alterations in mitochondrial function.^[31,32]



	Lybernin	ental	Contr	ol		Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% C	I M-H, Random, 95% CI
1.1.1 Leukopenia	-	~-					
Cheng 2019	2	25	3	25	1.8%	0.64 [0.10, 4.19]	
Huang 2019	0	20	1	20	0.8%	0.32 [0.01, 8.26]	
'u 2019	10	33	8	33	3.1%	1.36 [0.46, 4.04]	
'ue 2018	25	40	23	40	3.6%	1.23 [0.50, 3.02]	<u> </u>
Subtotal (95% CI)		118		118	9.4%	1.12 [0.59, 2.12]	—
otal events	37		35				
leterogeneity: Tau ² = est for overall effect: 2	0.00; Chi² = Z = 0.35 (P	= 1.09, d ' = 0.72)	f = 3 (P =	= 0.78);	$l^2 = 0\%$		
.1.2 Hypertension							
lan(1) 2018	33	60	3	57	2.8%	22.00 [6.18, 78.26]	
an(2) 2018	199	294	24	143	4.4%	10.39 [6.29, 17.16]	
ue 2018	2	40	0	40	0.9%	5.26 [0.24, 113.11]	
hou 2019	198	294	23	143	4.4%	10.76 [6.47, 17.89]	
ubtotal (95% CI)		688		383	12.4%	11.05 [7.85, 15.55]	
otal events	432		50				
eterogeneity: Tau ² =	0.00; Chi ² =	= 1.43, d	f = 3 (P =	= 0.70);	$ ^2 = 0\%$		
est for overall effect:	Z = 13.78 (P < 0.00	001)				
1.3 Hepatic dysfund	ction						
lan(1) 2018	9	60	3	57	2.6%	3.18 [0.81, 12.40]	+
an(2) 2018	92	294	28	143	4.4%	1.87 [1.16, 3.03]	
u 2019	2	33	3	33	1.9%	0.65 [0.10, 4.14]	
hou 2019	46	294	13	143	4.1%	1.85 [0.97, 3.56]	
ubtotal (95% CI)		681		376	13.0%	1.86 [1.29, 2.68]	
otal events	149		47				
eterogeneity: Tau ² =	0.00; Chi ² =	= 1.84, d	f = 3 (P =	= 0.61);	$I^2 = 0\%$		
est for overall effect:	Z = 3.33 (P	= 0.000	9)	,,			
1.4 Diarrhea		60	~	E-7	0.7%	5 49 14 40 00 000	
an(1) 2018	14	60	3	5/	2.1%	5.48 [1.48, 20.25]	
an(2) 2018	104	294	21	143	4.4%	3.18 [1.89, 5.35]	
luang 2019	1	20	3	20	1.4%	0.30 [0.03, 3.15]	
u 2019	6	33	9	33	3.0%	0.59 [0.18, 1.91]	
ue 2018	2	40	1	40	1.3%	2.05 [0.18, 23.59]	
hou 2019	103	294	21	143	4.3%	3.13 [1.86, 5.28]	· · · ·
Subtotal (95% CI)		741		436	17.0%	2.20 [1.17, 4.16]	\bullet
otal events	230		58				
leterogeneitv: I au≤ = i	0.29; Chi ² =	= 11.68,	df = 5 (P	= 0.04); 1² = 57%		
Test for overall effect:	Z = 2.43 (P	= 0.01)					
est for overall effect:	Z = 2.43 (P	= 0.01)					
est for overall effect:	Z = 2.43 (P niting	= 0.01)					
est for overall effect: 2 .1.5 Nausea and von Cheng 2019	Z = 2.43 (P niting 2	25	4	25	1.9%	0.46 [0.08, 2.75]	
est for overall effect: .1.5 Nausea and von Cheng 2019 Ian(1) 2018	2 = 2.43 (P niting 2 13	25 60	4 15	25 57	1.9% 3.7%	0.46 [0.08, 2.75] 0.77 [0.33, 1.81]	— <u>·</u>
est for overall effect: 2 2.1.5 Nausea and von Cheng 2019 Han(1) 2018 Huang 2019	2 = 2.43 (P niting 2 13 1	25 60 20	4 15 2	25 57 20	1.9% 3.7% 1.3%	0.46 [0.08, 2.75] 0.77 [0.33, 1.81] 0.47 [0.04, 5.69]	
Fest for overall effect: 7 2.1.5 Nausea and von Cheng 2019 Han(1) 2018 Huang 2019 Yu 2019	Z = 2.43 (P niting 2 13 1 11	25 60 20 33	4 15 2 12	25 57 20 33	1.9% 3.7% 1.3% 3.3%	0.46 [0.08, 2.75] 0.77 [0.33, 1.81] 0.47 [0.04, 5.69] 0.88 [0.32, 2.41]	
Fest for overall effect: 2 2.1.5 Nausea and von Cheng 2019 Han(1) 2018 Huang 2019 Yu 2019 Yue 2018	Z = 2.43 (P niting 2 13 1 11 11 12	25 60 20 33 40	4 15 2 12 9	25 57 20 33 40	1.9% 3.7% 1.3% 3.3% 3.3%	0.46 [0.08, 2.75] 0.77 [0.33, 1.81] 0.47 [0.04, 5.69] 0.88 [0.32, 2.41] 1.48 [0.54, 4.03]	
Fest for overall effect: 2 2.1.5 Nausea and von Cheng 2019 Han(1) 2018 Huang 2019 (u 2019 (ue 2018 Zhou 2019	Z = 2.43 (P niting 2 13 1 1 11 12 63	25 60 20 33 40 294	4 15 2 12 9 19	25 57 20 33 40 143	1.9% 3.7% 1.3% 3.3% 4.3%	0.46 [0.08, 2.75] 0.77 [0.33, 1.81] 0.47 [0.04, 5.69] 0.88 [0.32, 2.41] 1.48 [0.54, 4.03] 1.78 [1.02, 3.11]	
Test for overall effect: 2 2.1.5 Nausea and von Cheng 2019 Han(1) 2018 Huang 2019 Yu 2019 Yue 2018 Chou 2019 Subtotal (95% CI)	Z = 2.43 (P niting 2 13 1 1 1 12 63	25 60 20 33 40 294 472	4 15 2 12 9 19	25 57 20 33 40 143 318	1.9% 3.7% 1.3% 3.3% 3.3% 4.3% 17.8%	0.46 [0.08, 2.75] 0.77 [0.33, 1.81] 0.47 [0.04, 5.69] 0.88 [0.32, 2.41] 1.48 [0.54, 4.03] 1.78 [1.02, 3.11] 1.21 [0.82, 1.78]	
Fest for overall effect: <i>2</i> 2.1.5 Nausea and von Cheng 2019 4an(1) 2018 4uang 2019 7u 2019 7u 2018 7uou 2019 Subtotal (95% CI) Total events 4eterconentiv: Tau ² =	Z = 2.43 (P niting 2 13 1 1 1 12 63 102 0.01: Chi ² =	25 60 20 33 40 294 472	4 15 2 12 9 19 61 f = 5 (P =	25 57 20 33 40 143 318	1.9% 3.7% 1.3% 3.3% 4.3% 17.8%	0.46 [0.08, 2.75] 0.77 [0.33, 1.81] 0.47 [0.04, 5.69] 0.88 [0.32, 2.41] 1.48 [0.54, 4.03] 1.78 [1.02, 3.11] 1.21 [0.82, 1.78]	
est for overall effect: <i>i</i> . 1.5 Nausea and von cheng 2019 Ian(1) 2018 Iuang 2019 ⁷ u 2019 ⁷ u 2018 Iub 2	Z = 2.43 (P niting 2 13 1 1 12 63 102 0.01; Chi ² = Z = 0.96 (P	25 60 20 33 40 294 472 = 5.12, d	4 15 2 12 9 19 61 f = 5 (P =	25 57 20 33 40 143 318 = 0.40);	1.9% 3.7% 1.3% 3.3% 4.3% 17.8% ² = 2%	0.46 [0.08, 2.75] 0.77 [0.33, 1.81] 0.47 [0.04, 5.69] 0.88 [0.32, 2.41] 1.48 [0.54, 4.03] 1.78 [1.02, 3.11] 1.21 [0.82, 1.78]	
est for overall effect: <i>i</i> . 1.5 Nausea and von cheng 2019 Ian(1) 2018 Iuang 2019 Yu 2019 Yu 2019 Yu 2018 Iubtotal (95% CI) Yotal events Ieterogeneity: Tau ² = est for overall effect: <i>i</i> . 1.6 Hemoptysis	Z = 2.43 (P niting 2 13 1 11 12 63 102 0.01; Chi ² = Z = 0.96 (P	25 60 20 33 40 294 472 = 5.12, d '= 0.34)	4 15 2 12 9 19 61 f = 5 (P =	25 57 20 33 40 143 318 = 0.40);	1.9% 3.7% 1.3% 3.3% 4.3% 17.8%	0.46 [0.08, 2.75] 0.77 [0.33, 1.81] 0.47 [0.04, 5.69] 0.88 [0.32, 2.41] 1.48 [0.54, 4.03] 1.78 [1.02, 3.11] 1.21 [0.82, 1.78]	
est for overall effect: 2 2.1.5 Nausea and von Cheng 2019 tan(1) 2018 tuang 2019 tu 2019 tu 2019 tu 2019 tu 2018 thou 2019 subtotal (95% CI) Total events teterogeneity: Tau ² = - fest for overall effect: 2 2.1.6 Hemoptysis tan(1) 2018	2 = 2.43 (P) niting 2 13 1 11 12 63 102 0.01; Chi ² = 2 = 0.96 (P) 10	25 60 20 33 40 294 472 = 5.12, d = 0.34)	4 15 2 12 9 19 61 f = 5 (P =	25 57 20 33 40 143 318 = 0.40);	1.9% 3.7% 1.3% 3.3% 3.3% 4.3% 17.8% ² = 2% 2.3%	0.46 [0.08, 2.75] 0.77 [0.33, 1.81] 0.47 [0.04, 5.69] 0.88 [0.32, 2.41] 1.48 [0.54, 4.03] 1.78 [1.02, 3.11] 1.21 [0.82, 1.78] 5.50 [1.15, 26.32]	
est for overall effect: <i>i</i> . 1.5 Nausea and von theng 2019 tan(1) 2018 tuang 2019 tu 2019 tu 2018 hou 2019 tubtotal (95% CI) total events leterogeneity: Tau ² = : est for overall effect: <i>i</i> . 1.6 Hemoptysis lan(1) 2018 lan(2) 2018	2 = 2.43 (P) niting 2 13 1 11 12 63 102 0.01; Chi ² = 0.96 (P) 10 60	25 60 20 33 40 294 472 = 5.12, d = 0.34) 60 294	4 15 2 12 9 19 61 f = 5 (P = 2 13	25 57 20 33 40 143 318 = 0.40); 57 143	1.9% 3.7% 1.3% 3.3% 4.3% 17.8% ² = 2% 2.3% 4.1%	0.46 [0.08, 2.75] 0.77 [0.33, 1.81] 0.47 [0.04, 5.69] 0.88 [0.32, 2.41] 1.48 [0.54, 4.03] 1.78 [1.02, 3.11] 1.21 [0.82, 1.78] 5.50 [1.15, 26.32] 2.56 [1.36, 4.85]	
est for overall effect: 2 .1.5 Nausea and von cheng 2019 lan(1) 2018 luang 2019 fu 2019 fu 2019 fu 2018 lou 2019 subtotal (95% CI) otal events leterogeneity: Tau ² = est for overall effect: 2 .1.6 Hemoptysis lan(1) 2018 lan(2) 2018 lan(2) 2018	Z = 2.43 (P niting 2 13 1 11 12 63 102 0.01; Chi ² - Z = 0.96 (P 10 60 6	25 60 20 33 40 294 472 = 5.12, d = 0.34) 60 294 35	4 15 2 12 9 19 61 f = 5 (P =	25 57 20 143 318 = 0.40); 57 143 35	$\begin{array}{c} 1.9\%\\ 3.7\%\\ 1.3\%\\ 3.3\%\\ 4.3\%\\ 17.8\%\\ 1^2=2\%\\ 2.3\%\\ 4.1\%\\ 2.7\%\end{array}$	0.46 [0.08, 2.75] 0.77 [0.33, 1.81] 0.47 [0.04, 5.69] 0.88 [0.32, 2.41] 1.48 [0.54, 4.03] 1.78 [1.02, 3.11] 1.21 [0.82, 1.78] 5.50 [1.15, 26.32] 2.56 [1.36, 4.85] 1.24 [0.34, 4.53]	
iest for overall effect: 2 1.5 Nausea and von Cheng 2019 tan(1) 2018 tuang 2019 (u 2019 (u 2019 (u 2018 thou 2019 (ubtotal [95% CI]) fotal events telerogeneity: Tau ² = - est for overall effect: 2 .1.6 Hemoptysis tan(1) 2018 tan(2) 2018 tuang 2020 Vana 2020	Z = 2.43 (P niting 2 13 1 11 12 63 102 0.01; Chi2 = Z = 0.96 (P 10 60 60 61 1	25 60 20 33 40 294 472 = 5.12, d = 5.12, d = 0.34) 60 294 35 22	4 15 2 12 9 19 61 f = 5 (P = 2 13 5 1	25 57 20 33 40 143 318 = 0.40); 57 143 35 22	1.9% 3.7% 1.3% 3.3% 4.3% 17.8% ² = 2% 2.3% 4.1% 2.7% 1.0%	0.46 [0.08, 2.75] 0.77 [0.33, 1.81] 0.47 [0.04, 5.69] 0.88 [0.32, 2.41] 1.48 [0.54, 4.03] 1.78 [1.02, 3.11] 1.21 [0.82, 1.78] 5.50 [1.15, 26.32] 2.56 [1.36, 4.85] 1.24 [0.34, 4.52] 1.00 [0 6, 17 07]	
est for overall effect: .: .1.5 Nausea and von cheng 2019 tan(1) 2018 tuang 2019 'u 2019 'u 2018 thou 2019 tubtal (95% Cl) tubtal events tetrogeneity: Tau² = est for overall effect: .: .1.6 Hemoptysis tan(1) 2018 tan(2) 2018 tuang 2020 Vang 2020 Vang 2020 Vang 2020	Z = 2.43 (P niting 2 13 1 11 12 63 102 0.01; Chi2 = Z = 0.96 (P 10 60 6 1 58	25 60 20 33 40 294 472 = 5.12, d 294 472 = 0.34) 60 294 35 22 294	4 15 2 19 9 9 9 19 61 f = 5 (P = 2 13 5 1 11	25 57 20 33 40 143 318 = 0.40); 57 143 35 22 2143	1.9% 3.7% 1.3% 3.3% 4.3% 17.8% 12 ² = 2% 2.3% 4.1% 2.7% 1.0% 4.0%	0.46 [0.08, 2.75] 0.77 [0.33, 1.81] 0.47 [0.04, 5.69] 0.88 [0.32, 2.41] 1.48 [0.54, 4.03] 1.78 [1.02, 3.11] 1.21 [0.82, 1.78] 5.50 [1.15, 26.32] 2.56 [1.36, 4.85] 1.24 [0.34, 4.52] 1.00 [0.06, 17.07] 2.95 [1.50, 5.81]	
Test for overall effect: 2 2.1.5 Nausea and von Cheng 2019 tan(1) 2018 tuang 2019 'u 2018 thou 2019 Bubtotal (95% CI) 'otal events telerogeneity: Tau ² = 'est for overall effect: 2 t.1.6 Hemoptysis tan(1) 2018 tan(2) 2018 tuang 2020 Vang 2020 Vang 2020 Subtotal (95% CI)	Z = 2.43 (P niting 2 13 1 11 12 63 102 0.01; Chi2 = 2 = 0.96 (P 10 60 6 1 58	25 60 20 33 40 294 472 = 5.12, d = 0.34) 60 294 35 22 294 35 22 2795	4 15 2 12 9 19 61 f = 5 (P = 2 13 5 1 1	25 57 20 33 40 143 318 = 0.40); 57 143 35 22 143 400	1.9% 3.7% 1.3% 3.3% 4.3% 17.8% 1 ² = 2% 2.3% 4.1% 2.7% 1.0% 4.0%	0.46 [0.08, 2.75] 0.77 [0.33, 1.81] 0.47 [0.04, 5.69] 0.88 [0.32, 2.41] 1.48 [0.54, 4.03] 1.78 [1.02, 3.11] 1.21 [0.82, 1.78] 5.50 [1.15, 26.32] 2.56 [1.36, 4.85] 1.24 [0.34, 4.52] 1.00 [0.06, 17, 0.7] 2.95 [1.50, 5.81]	
est for overall effect: <i>i</i> . 1.5 Nausea and von theng 2019 Ian(1) 2018 Iuang 2019 (v 2019 (v 2018 hou 2019 (v 2018 Iuang 2019 (v 2018 Ieterogeneity: Tau ² = est for overall effect: <i>i</i> . 1.6 Hemoptysis Ian(2) 2018 Iuang 2020 Vang 2020 Iuang 2020 Iu	Z = 2.43 (P niting 2 13 1 11 12 63 0.01; Chi ² Z = 0.96 (P 10 60 6 1 58 135	25 60 20 33 40 294 472 = 5.12, d '= 0.34) 60 294 35 22 294 705	4 15 2 12 9 19 61 f = 5 (P = 2 13 5 1 11	25 57 20 33 40 143 318 = 0.40); 57 143 35 22 143 400	1.9% 3.7% 1.3% 3.3% 4.3% 17.8% 1 ² = 2% 2.3% 4.1% 2.7% 1.0% 4.0% 14.2 %	0.46 [0.08, 2.75] 0.77 [0.33, 1.81] 0.47 [0.04, 5.69] 0.88 [0.32, 2.41] 1.48 [0.54, 4.03] 1.78 [1.02, 3.11] 1.21 [0.82, 1.78] 5.50 [1.15, 26.32] 2.56 [1.36, 4.85] 1.24 [0.34, 4.52] 1.00 [0.06, 17.07] 2.95 [1.50, 5.81] 2.59 [1.71, 3.93]	
Test for overall effect: 2 2.1.5 Nausea and von Cheng 2019 tan(1) 2018 tuang 2019 'u 2018 thou 2019 Bubtotal (95% CI) otal events telerogeneity: Tau ² = test for overall effect: 2 t.1.6 Hemoptysis tan(1) 2018 tan(2) 2018 tuang 2020 Vang 2020 Subtotal (95% CI) otal events teletrogeneity: Tau ² = zet for overall effect: 3	Z = 2.43 (P niting 2 13 1 1 12 63 102 0.01; Chi ² = Z = 0.96 (P 10 60 6 1 58 105 2 58 105 2 58	25 60 20 33 40 294 472 = 5.12, d = 0.34) 60 294 35 22 294 35 22 294 705 = 2.72, d	4 15 2 9 19 61 f = 5 (P = 2 13 5 1 11 11 5 1 11 5 1 0 1)	25 57 20 33 40 143 318 57 143 35 22 2143 400 = 0.61);	$\begin{array}{c} 1.9\%\\ 3.7\%\\ 1.3\%\\ 3.3\%\\ 4.3\%\\ 17.8\%\\ 1^2=2\%\\ 2.3\%\\ 4.1\%\\ 2.7\%\\ 1.0\%\\ 4.0\%\\ 14.2\%\\ 1^2=0\%\\ 1^2=0\%\\ 1.0\%\\ 1.0\%\\ 1^2=0\%\\ 1.0\%\\ 1.0\%\\ 1^2=0\%\\ 1.0\%$	0.46 [0.08, 2.75] 0.77 [0.33, 1.81] 0.47 [0.04, 5.69] 0.88 [0.32, 2.41] 1.48 [0.54, 4.03] 1.78 [1.02, 3.11] 1.21 [0.82, 1.78] 5.50 [1.15, 26.32] 2.56 [1.36, 4.85] 1.24 [0.34, 4.52] 1.00 [0.06, 17,07] 2.95 [1.50, 5.81] 2.59 [1.71, 3.93]	
est for overall effect: <i>i</i> . 1.5 Nausea and von theng 2019 tan(1) 2018 tu 2019 tu 2019 tu 2019 tu 2019 tu 2019 tu 2018 tou 2019 tu 2019 tu 2018 tu 2019 tu 2019 tu 2019 tu 2019 tu 2019 tu 2018 tan(2) 2018 tan(2) 2018 tan(2) 2018 tan(2) 2018 tan(2) 2018 tan(2) 2018 tan(2) 2018 tan(2) 2018 tan(2) 2018 tu 2020 Vang 2020 Vang 2020 Vang 2020 tu 2019 tu tu totat (95% CI) otal events leterogeneity: Tau ² = : est for overall effect: <i>i</i> .	Z = 2.43 (P niting 2 3 1 1 1 1 6 3 102 0.01; Chi ² = 2 2 = 0.96 (P 10 60 6 1 58 135 0.00; Chi ² = 2 8 2 3 2 2 2 4.48 (P	25 60 20 33 40 294 472 = 5.12, d = 0.34) 60 294 35 22 294 35 22 294 35 22 294 35 22 294 35 22 294 35 22 294 35 22 294	4 15 2 12 9 19 61 f = 5 (P = 2 13 5 1 11 11 5 2 f = 4 (P = 01)	25 57 20 33 40 143 318 = 0.40); 77 143 35 22 143 400 = 0.61);	1.9% 3.7% 1.3% 3.3% 4.3% 17.8% 1 ² = 2% 2.3% 4.1% 2.7% 1.0% 4.0% 14.2% 1 ² = 0%	0.46 [0.08, 2.75] 0.77 [0.33, 1.81] 0.47 [0.04, 5.69] 0.88 [0.32, 2.41] 1.48 [0.54, 4.03] 1.78 [1.02, 3.11] 1.21 [0.82, 1.78] 5.50 [1.15, 26.32] 2.56 [1.36, 4.85] 1.24 [0.34, 4.52] 1.00 [0.06, 17.07] 2.95 [1.50, 5.81] 2.59 [1.71, 3.93]	
est for overall effect: .; .1.5 Nausea and von heng 2019 tan(1) 2018 tuang 2019 'u 2019 'u 2018 hou 2019 'u 2018 touag 2019 'u 2019 'u 2018 teterogeneity: Tau ² = est for overall effect: ; .1.6 Hemoptysis tan(1) 2018 tuang 2020 Yang 2020 hou 2019 teterogeneity: Tau ² = 'est for overall effect: ; teterogeneity: Tau ² = 'est for overall effect: ; 'otal events 'eterogeneity: Tau ² = 'est for overall effect: ; .1.7 Pulmonary infect	Z = 2.43 (P niting 2 13 1 1 1 12 63 102 0.01; Chi ² = 0.96 (P 10 60 6 1 58 135 0.00; Chi ² = Z = 4.48 (P ction	25 60 20 33 40 294 472 = 5.12, d 472 = 5.12, d 294 35 22 294 35 22 294 5 22 294 5 22 294 5 22 294 5 22 294 5 22 5 22	4 15 2 19 9 61 f = 5 (P = 2 13 5 1 11 11 32 f = 4 (P = 01)	25 57 20 33 40 143 318 = 0.40); 57 143 35 22 143 400 = 0.61);	1.9% 3.7% 1.3% 3.3% 4.3% 17.8% 1 ² = 2% 2.3% 4.1% 2.7% 4.1% 2.7% 4.0% 14.2% 1 ² = 0%	0.46 [0.08, 2.75] 0.77 [0.33, 1.81] 0.47 [0.04, 5.69] 0.88 [0.32, 2.41] 1.48 [0.54, 4.03] 1.78 [1.02, 3.11] 1.21 [0.82, 1.78] 5.50 [1.15, 26.32] 2.56 [1.36, 4.85] 1.24 [0.34, 4.52] 1.00 [0.06, 17.07] 2.95 [1.50, 5.81] 2.59 [1.71, 3.93]	
Test for overall effect: <i>i</i> . 1.5 Nausea and von Cheng 2019 tan(1) 2018 tuang 2019 'u 2019 'u 2018 thou 2019 'u 2018 thou 2019 'u 2014 'u 2018 thou 2019 'u bubtotal (95% CI) 'otal events telerogeneity: Tau ² = 'est for overall effect: <i>i</i> 'u ang 2020 'ububtotal (95% CI) 'otal events telerogeneity: Tau ² = 'est for overall effect: <i>i</i>	Z = 2.43 (P niting 2 13 1 1 1 2 63 102 0.01; Chi ² = 0.96 (P 10 6 1 58 135 0.00; Chi ² = 4.48 (P ction 7	25 25 26 20 20 33 34 472 = 5.12, d 472 = 0.34) 60 294 35 = 2.72, d - < 0.000 35	$\begin{array}{c} 4\\ 15\\ 2\\ 12\\ 9\\ 9\\ 19\\ 19\\ 19\\ 11\\ 1\\ 1\\ 1\\ 1\\ 1\\ 1\\ 1\\ 1\\ 1\\ 1\\ 1\\ 1$	25 57 20 33 40 143 318 € 0.40); 57 143 35 22 143 400 € 0.61); 35	1.9% 3.7% 1.3% 3.3% 4.3% 17.8% 1 ² = 2% 2.3% 4.1% 2.7% 1.0% 4.0% 14.2% 1 ² = 0% 2.9%	0.46 [0.08, 2.75] 0.77 [0.33, 1.81] 0.47 [0.04, 5.69] 0.88 [0.32, 2.41] 1.48 [0.54, 4.03] 1.78 [1.02, 3.11] 1.21 [0.82, 1.78] 5.50 [1.15, 26.32] 2.56 [1.36, 4.85] 1.24 [0.34, 4.52] 1.00 [0.06, 17.07] 2.95 [1.71, 3.93] 1.21 [0.36, 4.04]	
Test for overall effect: : .1.5 Nausea and von Cheng 2019 tan(1) 2018 tuang 2019 'u 2014 'u 2015 'u 2018 tous contrait 'u 2019 Subtotal (95% CI) 'otal events tan(1) 2018 tan(2) 2018 tuang 2020 Vang 2020 'bubtotal (95% CI) 'otal events teterogeneity: Tau ² = : 'est for overall effect: : .1.7 Pulmonary infectuang 2020 Vang 2020	Z = 2.43 (P niting 2 3 1 1 1 1 2 63 102 0.01; Chi ² = 2 0.00; Chi ² = 10 60 6 1 58 135 0.00; Chi ² = 2 4.48 (P z = 4.48 (P	25 60 20 33 40 294 472 = 5.12, d 294 472 = 0.34) 60 294 35 22 294 52 2 294 52 2 294 52 2 294 52 2 294 52 5 22 5 52 53 52 53 52	4 15 2 12 9 9 19 19 61 1 5 1 11 11 5 5 1 1 11 11 5 5 1 1 11 1	25 57 20 33 40 143 318 57 7 143 35 22 143 400 57 6 0.61); 35 22	1.9% 3.7% 1.3% 3.3% 4.3% 17.8% 1 ² = 2% 2.3% 4.1% 2.7% 4.0% 14.2% 1 ² = 0% 1 ² = 0%	0.46 [0.08, 2.75] 0.77 [0.33, 1.81] 0.47 [0.04, 5.69] 0.88 [0.32, 2.41] 1.48 [0.54, 4.03] 1.78 [1.02, 3.11] 1.21 [0.82, 1.78] 5.50 [1.15, 26.32] 2.56 [1.36, 4.85] 1.24 [0.34, 4.52] 1.00 [0.06, 17,07] 2.95 [1.50, 5.81] 2.59 [1.71, 3.93] 1.21 [0.36, 4.04] 2.10 [0.18, 25.01]	
est for overall effect: <i>i</i> . 1.5 Nausea and von theng 2019 tan(1) 2018 tuang 2019 tu 2019 tu 2018 hou 2019 vator 195% closed (95% Cl) otal events leterogeneity: Tau ² = = est for overall effect: <i>i</i> . 1.6 Hemoptysis tan(1) 2018 tuang 2020 tuang 2020 hou 2019 vator 195% Cl) otal events leterogeneity: Tau ² = est for overall effect: <i>i</i> . 1.7 Pulmonarg infect tuang 2020 hou 2019 vang 2020 hou 2019 tubtotal events leterogeneity: Tau ² =	Z = 2.43 (P niting 2 13 1 11 12 63 102 0.01; Chi ² = 2 0.96 (P 10 60 6 1 1 58 0.00; Chi ² = 2 Z = 4.48 (P ction 7 2 28	25 25 20 20 33 30 472 = 5.12, d 294 472 = 0.34) 60 294 472 = 0.34) 60 294 705 = 2.72, d 0.000 = 2.72, d 35 22 294	4 15 2 12 12 12 19 9 19 61 1 f = 5 (P = 1 13 5 1 1 11 11 11 11 11 11 11 11 11 11 11	255 57 20 33 40 143 318 = 0.40); 57 143 35 22 143 400 = 0.61); 35 22 143	1.9% 3.7% 1.3% 3.3% 4.3% 17.8% 1 ² = 2% 2.3% 4.1% 2.7% 1.0% 14.2% 1 ² = 0% 1 ² = 0%	0.46 [0.08, 2.75] 0.77 [0.33, 1.81] 0.47 [0.04, 5.69] 0.88 [0.32, 2.41] 1.48 [0.54, 4.03] 1.78 [1.02, 3.11] 1.21 [0.82, 1.78] 5.50 [1.15, 26.32] 2.56 [1.36, 4.85] 1.24 [0.34, 4.52] 1.00 [0.06, 17.07] 2.95 [1.50, 5.81] 2.59 [1.71, 3.93]	
est for overall effect: <i>i</i> . 1.5 Nausea and von theng 2019 than (1) 2018 thuang 2019 tu 2019 tu 2019 tu 2019 tu 2018 hou 2019 tu 2018 tu 2018 tu 2018 tu 2019 tu 2019 tu 2019 tu 2019 tu 2018 tan (1) 2018 tan (2) 2018 tan (2) 2018 tu 2020 thou 2019 tu 2020 tu 2020 t	Z = 2.43 (P niting 2 3 1 1 1 1 2 63 102 0.01; Chi ² = Z = 0.96 (P 10 60 6 1 58 135 Z = 4.48 (P ction 7 2 28	255 60 20 33 40 294 472 = 5.12, d = = 0.34) 60 294 35 222 224 705 = 2.72, d 0.000 35 222 224 351	4 15 2 9 9 19 61 1 5 1 1 11 32 2 13 5 1 1 11 32 2 13 2 13	255 57 20 33 40 143 318 57 7 143 35 22 143 400 5 6 (0.61); 22 143 400 5 7 2 143 20	1.9% 3.7% 1.3% 3.3% 4.3% 17.8% 1 ² = 2% 2.3% 4.1% 2.7% 4.0% 14.2% 1 ² = 0% 1 ² = 0% 2.9% 1.3% 3.8% 8.0%	0.46 [0.08, 2.75] 0.77 [0.33, 1.81] 0.47 [0.04, 5.69] 0.88 [0.32, 2.41] 1.48 [0.54, 4.03] 1.78 [1.02, 3.11] 1.21 [0.82, 1.78] 5.50 [1.15, 26.32] 2.56 [1.36, 4.85] 1.24 [0.34, 4.52] 1.00 [0.06, 17.07] 2.95 [1.50, 5.81] 2.59 [1.71, 3.93] 1.21 [0.36, 4.04] 2.10 [0.18, 25.01] 1.57 [0.72, 3.42] 1.57 [0.72, 3.42]	
Test for overall effect: .: .1.5 Nausea and von >heng 2019 tan(1) 2018 tuang 2019 'u 2019 'ue 2018 'hou 2019 'ue 2018 'hou 2019 'ubtotal (95% Cl) 'otal events leterogeneity: Tau ² = : 'est for overall effect: .: '1.6 Hemoptysis tan(1) 2018 tuang 2020 'hou 2019 'ubtotal (95% Cl) 'otal events feterogeneity: Tau ² = : 'est for overall effect: : 'otal events feterogeneity: Tau ² = : 'est for overall effect: : 'uang 2020 'hou 2019 'uang 2020 'hou 2019 'uabtotal (95% Cl) 'otal events	Z = 2.43 (P niting 2 13 1 11 12 63 102 0.01; Chi ² = 0.96 (P 10 60 6 1 12 58 135 0.00; Chi ² = 135 0.00; Chi ² = 2 X = 4.48 (P 2 28 37	25 60 20 33 40 294 472 = 5.12, d 472 = 5.12, d 472 = 0.34) 60 294 35 22 294 705 = 2.72, d 0.000 35 22 294 351	$\begin{array}{c} 4 \\ 15 \\ 2 \\ 9 \\ 9 \\ 19 \\ 61 \\ 61 \\ 13 \\ 5 \\ 1 \\ 11 \\ 11 \\ 32 \\ 4 \\ 7 \\ 4 \\ 10 \\ 10 \\ 11 \\ 11 \\ 11 \\ 11 \\ 12 \\ 12$	25 57 20 33 40 143 318 = 0.40); 57 143 35 22 143 400 = 0.61); 22 143 200	1.9% 3.7% 1.3% 3.3% 4.3% 17.8% 1 ² = 2% 2.3% 4.1% 2.7% 1.0% 4.0% 14.2% 1 ² = 0% 2.9% 1.3% 3.8% 8.0%	0.46 [0.08, 2.75] 0.77 [0.33, 1.81] 0.47 [0.04, 5.69] 0.88 [0.32, 2.41] 1.48 [0.54, 4.03] 1.78 [1.02, 3.11] 1.21 [0.82, 1.78] 2.56 [1.36, 4.85] 1.24 [0.34, 4.52] 1.00 [0.06, 17, 07] 2.95 [1.50, 5.81] 2.59 [1.71, 3.93] 1.21 [0.36, 4.04] 2.10 [0.18, 25.01] 1.57 [0.72, 3.42] 1.49 [0.79, 2.80]	
Test for overall effect: <i>i</i> 1.5 Nausea and von Cheng 2019 tan(1) 2018 tuang 2019 'u 2019 'u 2019 'u 2019 'u 2018 thou 2019 Subtotal (95% CI) 'otal events telerogeneity: Tau ² = 'est for overall effect: <i>i</i> 1.6 Hemoptysis tan(1) 2018 tan(2) 2018 tuang 2020 Vang 2020 thou 2019 subtotal (95% CI) 'otal events telerogeneity: Tau ² = : 'est for overall effect: <i>i</i> 1.1.7 Pulmonary infect tuang 2020 Vang 2020 thou 2019 subtotal (95% CI) 'otal events telerogeneity: Tau ² = : 'est for overall effect: :	Z = 2.43 (P niting 2 13 1 11 12 63 102 0.01; Chi ² = 2 0.01; Chi ² = 10 60 6 1 10 60 6 1 10 58 135 0.00; Chi ² = 2 8 37 0.00; Chi ² = 2 8 37 0.00; Chi ² = 2 8 37 0.00; Chi ² = 2 8 37 0.00; Chi ² = 2 8 37	25 60 20 33 40 294 472 = 5.12, d 472 = 5.12, d 472 = 0.34) 60 294 35 22 294 705, d < 0.000 35 22 294 705, d < 0.000 35 22 294 35 = 2.72, d 0 294 472 = 0.011 294 472 = 0.011 294 472 = 0.011 294 294 472 = 0.011 294 294 472 = 0.011 294 472 = 0.011 294 472 = 0.011 294 472 = 0.011 294 472 = 0.011 294 472 = 0.011 294 472 = 0.011 294 472 = 0.011 294 294 472 = 0.011 294 472 = 0.011 294 294 472 = 0.011 294 294 294 294 294 294 294 294 294 294	$\begin{array}{c} 4\\ 15\\ 2\\ 9\\ 9\\ 19\\ 61\\ f=5 \ (P=\\ 2\\ 13\\ 5\\ 1\\ 1\\ 11\\ 32\\ f=4 \ (P=\\ 01)\\ 6\\ 1\\ 9\\ 16\\ f=2 \ (P=\\ 12\\ ($	25 57 20 33 40 143 318 = 0.40); 57 143 35 22 143 400 = 0.61); 35 22 21 143 20 = 0.90);	1.9% 3.7% 1.3% 3.3% 4.3% 17.8% 1 ² = 2% 2.3% 4.1% 2.7% 4.0% 14.2% 1 ² = 0% 1.3% 3.8% 8.0% 1 ² = 0%	0.46 [0.08, 2.75] 0.77 [0.33, 1.81] 0.47 [0.04, 5.69] 0.88 [0.32, 2.41] 1.48 [0.54, 4.03] 1.78 [1.02, 3.11] 1.21 [0.82, 1.78] 2.56 [1.36, 4.85] 1.24 [0.34, 4.52] 1.00 [0.06, 17,07] 2.95 [1.50, 5.81] 2.59 [1.71, 3.93] 1.21 [0.36, 4.04] 2.10 [0.18, 25.01] 1.57 [0.72, 3.42] 1.49 [0.79, 2.80]	
est for overall effect: <i>i</i> . 1.5 Nausea and von theng 2019 tan(1) 2018 tuang 2019 'u 2019 'u 2019 'u 2019 'u 2018 hou 2019 'u 2018 tubtotal (95% CI) otal events leterogeneity: Tau ² = : est for overall effect: <i>i</i> . 1.6 Hemoptysis lan(1) 2018 tan(2) 2018 tuang 2020 Vang 202	Z = 2.43 (P niting 2 3 1 1 1 1 2 63 102 0.01; Chi ² = 0.96 (P 10 60 6 1 2 58 135 0.00; Chi ² = 2 8 37 0.00; Chi ² = 2 8 37 0.00; Chi ² = 2 8 37 0.00; Chi ² = 2 2 8	$\begin{array}{c} 25\\ 60\\ 20\\ 33\\ 40\\ 294\\ 472\\ = 5.12, d\\ 472\\ = 0.34)\\ 60\\ 294\\ 472\\ = 0.34)\\ 60\\ 294\\ 472\\ = 0.34)\\ 60\\ 294\\ 705\\ = 2.72, d\\ 0.000\\ 35\\ 22\\ 294\\ 35\\ 22\\ 294\\ 35\\ = 2.72, d\\ 0.000\\ 35\\ 22\\ 294\\ 35\\ 22\\ 20\\ 294\\ 35\\ 22\\ 20\\ 20\\ 20\\ 20\\ 20\\ 20\\ 20\\ 20\\ 20$	$\begin{array}{c} 4\\ 15\\ 2\\ 9\\ 9\\ 19\\ 61\\ f=5 \ (P=\\ 2\\ 13\\ 5\\ 1\\ 1\\ 1\\ 1\\ 1\\ 1\\ 1\\ 1\\ 1\\ 1\\ 1\\ 1\\ 1\\$	255 57 20 33 40 143 318 = 0.40); 577 143 35 22 213 400 = 0.61); 22 2143 400 = 0.61); 22 2143 200 200 = 0.90);	1.9% 3.7% 1.3% 3.3% 4.3% 17.8% 1 ² = 2% 2.3% 4.1% 2.7% 4.0% 14.2% 1 ² = 0% 2.9% 1.3% 3.8% 8.0%	0.46 [0.08, 2.75] 0.77 [0.33, 1.81] 0.47 [0.04, 5.69] 0.88 [0.32, 2.41] 1.48 [0.54, 4.03] 1.78 [1.02, 3.11] 1.21 [0.82, 1.78] 2.56 [1.36, 4.85] 1.24 [0.34, 4.52] 1.00 [0.06, 17,07] 2.95 [1.50, 5.81] 2.59 [1.71, 3.93] 1.21 [0.36, 4.04] 2.10 [0.18, 25.01] 1.57 [0.72, 3.42] 1.49 [0.79, 2.80]	
est for overall effect: .: .1.5 Nausea and von heng 2019 han(1) 2018 huang 2019 'u 2018 hou 2019 'u 2018 hou 2019 'u 2018 hou 2019 'u 2018 iderogeneity: Tau ² = : est for overall effect: : .1.6 Hemoptysis han(1) 2018 tauag 2020 Yang 2020 Yotal events leterogeneity: Tau ² = : est for overall effect: : .1.7 Pulmonary infect Yang 2020 Yang 2020 <t< td=""><td>Z = 2.43 (P niting 2 13 1 1 12 63 102 0.01; Chi² = 0.03; Chi² = Z = 0.96 (P 10 60 6 1 58 135 0.00; Chi² = Z = 4.48 (P ction 7 2 28 37 0.00; Chi² = 28 37 0.00; Chi² = 28</td><td>25 60 20 33 40 294 472 = 5.12, d 472 = 5.12, d 472 = 5.12, d 472 = 5.12, d 472 = 5.12, d 60 294 355 = 2.72, d 355 = 2.72, d 351 = 0.000 294 351 = 0.000 294 355 = 0.000 294 355 222 294 355 = 0.000 294 355 222 294 355 222 294 200 294 294 294 200 294 294 200 294 294 200 294 294 200 294 200 294 294 200 294 200 294 200 294 200 294 200 294 200 294 200 294 200 294 200 200 294 200 294 200 204 200 294 200 204 200 204 200 204 200 204 200 204 204</td><td>$\begin{array}{c} 4 \\ 15 \\ 2 \\ 9 \\ 9 \\ 19 \\ 61 \\ f = 5 \\ (P = 5 \\ 13 \\ 5 \\ 1 \\ 11 \\ 11 \\ 11 \\ f = 4 \\ (P = 0 \\ 01) \\ 6 \\ 1 \\ 9 \\ 16 \\ f = 2 \\ (P = 0 \\ (P = 0 \\ 0 \\ 1 \\ 0 \\ 1 \\ 0 \\ 0 \\ 1 \\ 0 \\ 0 \\$</td><td>25 57 20 33 40 143 318 57 7 143 35 22 143 400 6 0.611; 35 22 143 200 6 0.90;; 7 57</td><td>1.9% 3.7% 1.3% 3.3% 4.3% 17.8% 1² = 2% 2.3% 4.1% 2.7% 1.0% 14.2% 1² = 0% 2.9% 1.3% 3.8% 8.0%</td><td>0.46 [0.08, 2.75] 0.77 [0.33, 1.81] 0.47 [0.04, 5.69] 0.88 [0.32, 2.41] 1.48 [0.54, 4.03] 1.78 [1.02, 3.11] 1.21 [0.82, 1.78] 5.50 [1.15, 26.32] 2.56 [1.36, 4.85] 1.24 [0.34, 4.52] 1.00 [0.06, 17, 07] 2.95 [1.50, 5.81] 2.59 [1.71, 3.93] 1.21 [0.36, 4.04] 2.10 [0.18, 25.01] 1.57 [0.72, 3.42] 1.49 [0.79, 2.80]</td><td></td></t<>	Z = 2.43 (P niting 2 13 1 1 12 63 102 0.01; Chi ² = 0.03; Chi ² = Z = 0.96 (P 10 60 6 1 58 135 0.00; Chi ² = Z = 4.48 (P ction 7 2 28 37 0.00; Chi ² = 28 37 0.00; Chi ² = 28	25 60 20 33 40 294 472 = 5.12, d 472 = 5.12, d 472 = 5.12, d 472 = 5.12, d 472 = 5.12, d 60 294 355 = 2.72, d 355 = 2.72, d 351 = 0.000 294 351 = 0.000 294 355 = 0.000 294 355 222 294 355 = 0.000 294 355 222 294 355 222 294 200 294 294 294 200 294 294 200 294 294 200 294 294 200 294 200 294 294 200 294 200 294 200 294 200 294 200 294 200 294 200 294 200 294 200 200 294 200 294 200 204 200 294 200 204 200 204 200 204 200 204 200 204 204	$\begin{array}{c} 4 \\ 15 \\ 2 \\ 9 \\ 9 \\ 19 \\ 61 \\ f = 5 \\ (P = 5 \\ 13 \\ 5 \\ 1 \\ 11 \\ 11 \\ 11 \\ f = 4 \\ (P = 0 \\ 01) \\ 6 \\ 1 \\ 9 \\ 16 \\ f = 2 \\ (P = 0 \\ (P = 0 \\ 0 \\ 1 \\ 0 \\ 1 \\ 0 \\ 0 \\ 1 \\ 0 \\ 0 \\$	25 57 20 33 40 143 318 57 7 143 35 22 143 400 6 0.611; 35 22 143 200 6 0.90;; 7 57	1.9% 3.7% 1.3% 3.3% 4.3% 17.8% 1 ² = 2% 2.3% 4.1% 2.7% 1.0% 14.2% 1 ² = 0% 2.9% 1.3% 3.8% 8.0%	0.46 [0.08, 2.75] 0.77 [0.33, 1.81] 0.47 [0.04, 5.69] 0.88 [0.32, 2.41] 1.48 [0.54, 4.03] 1.78 [1.02, 3.11] 1.21 [0.82, 1.78] 5.50 [1.15, 26.32] 2.56 [1.36, 4.85] 1.24 [0.34, 4.52] 1.00 [0.06, 17, 07] 2.95 [1.50, 5.81] 2.59 [1.71, 3.93] 1.21 [0.36, 4.04] 2.10 [0.18, 25.01] 1.57 [0.72, 3.42] 1.49 [0.79, 2.80]	
est for overall effect: : .1.5 Nausea and von theng 2019 tan(1) 2018 tuang 2019 tu 2019 tu 2018 hou 2019 tu 2018 hou 2019 tubtotal (95% CI) total events leterogeneity: Tau ² = est for overall effect: : .1.6 Hemoptysis tan(1) 2018 tan(2) 2018 tan(2) 2018 tan(2) 2018 tan(2) 2018 tuang 2020 thou 2019 tubtotal (95% CI) total events leterogeneity: Tau ² = iest for overall effect: : .1.7 Pulmonary infect tuang 2020 Vang 2020 Vang 2020 Vang 2020 Vang 2020 Vang 2020 Vang 2020 Vang 2020 Vang 2020 Vang 2020 total events leterogeneity: Tau ² = iest for overall effect: : .1.8 Dyspnea tuang 2020	Z = 2.43 (P niting 2 13 1 1 1 12 63 102 0.01; Chi ² = 2 3 0.00; Chi ² = 2 4.48 (P 2 2 8 0.00; Chi ² = 2 8 0.00; Chi ² = 2 0.00; Chi ² = 2 0.0	$\begin{array}{c} 25\\ 60\\ 20\\ 33\\ 40\\ 294\\ 472\\ = 5.12, d\\ 472\\ = 0.34)\\ 60\\ 294\\ 35\\ 22\\ 294\\ 705\\ 22\\ 294\\ 705\\ 22\\ 294\\ 351\\ = 0.21, d\\ 351\\ = 0.221\\ 351\\ \end{array}$	$\begin{array}{c} 4\\ 15\\ 2\\ 2\\ 12\\ 9\\ 9\\ 19\\ 61\\ f=5 \ (P=\\ 2\\ 13\\ 5\\ 1\\ 11\\ 11\\ 11\\ 11\\ 11\\ 11\\ 11\\ 11\\ $	255 57 20 33 40 143 318 57 7 143 35 22 143 400 ¢ 0.61); 22 143 200 ¢ 0.90); 355 22 2 2 43 200 ¢ 0.90);	1.9% 3.7% 1.3% 3.3% 4.3% 17.8% 17.8% 12 = 2% 2.3% 4.1% 2.7% 4.0% 14.2% 12 = 0% 2.9% 1.3% 3.8% 8.0% 1 ² = 0%	0.46 [0.08, 2.75] 0.77 [0.33, 1.81] 0.47 [0.04, 5.69] 0.88 [0.32, 2.41] 1.48 [0.54, 4.03] 1.78 [1.02, 3.11] 1.21 [0.82, 1.78] 2.56 [1.36, 4.85] 1.24 [0.34, 4.52] 1.00 [0.06, 17.07] 2.95 [1.50, 5.81] 2.59 [1.71, 3.93] 1.21 [0.36, 4.04] 2.10 [0.18, 25.01] 1.57 [0.72, 3.42] 1.49 [0.79, 2.80]	
est for overall effect: : .1.5 Nausea and von theng 2019 tan(1) 2018 tuang 2019 'u 2019 'u 2019 'u 2013 'u 2014 'u 2015 'u 2016 'u 2018 thou 2019 'u 2018 teterogeneity: Tau ² = est for overall effect: : .1.6 Hemoptysis tan(2) 2018 tuang 2020 Yang 2020 hou 2019 teterogeneity: Tau ² = est for overall effect: : .1.7 Pulmonary infectuang 2020 Yang 2020 thou 2019 subtotal (95% CI) total events leterogeneity: Tau ² = est for overall effect: : .1.7 Pulmonary infectuang 2020 thou 2019 subtotal (95% CI) total events leterogeneity: Tau ² = 'est for overall effect: : .1.8 Dyspnea tuang 2020 Yang 2020 Yang 2020	Z = 2.43 (P niting 2 13 1 11 12 63 102 0.01; Chi ² = 0.96 (P 10 60 6 1 1 58 135 0.00; Chi ² = 28 37 0.00; Chi ² = 37 0.00; Chi ² = 28 37 0.00; Chi ² = 28 37 0.00; Chi ² = 28 37 0.00; Chi ² = 28 37 0.00; Chi ² = 37 0.00; Chi ² = 28 37 0.00; Chi ² = 37 0.00; Chi ² = 37	$\begin{array}{c} 25\\ 60\\ 20\\ 33\\ 40\\ 294\\ 472\\ =5.12, d\\ 472\\ =5.12, d\\ 472\\ =0.34\\ \end{array}$	$\begin{array}{c} 4 \\ 15 \\ 2 \\ 9 \\ 9 \\ 19 \\ 19 \\ 61 \\ 61 \\ 13 \\ 5 \\ 1 \\ 11 \\ 11 \\ 32 \\ 32 \\ 61 \\ 10 \\ 10 \\ 10 \\ 10 \\ 10 \\ 10 \\ 10$	255 57 20 33 40 143 318 57 7143 35 22 143 400 57 6.061); 22 22 20 6 5,090); 35 22 22 22 22 22	1.9% 3.7% 1.3% 3.3% 4.3% 17.8% 1 ² = 2% 2.3% 4.1% 2.7% 1.0% 4.0% 14.2% 1 ² = 0% 2.9% 1.3% 3.8% 8.0% 1 ² = 0%	0.46 [0.08, 2.75] 0.77 [0.33, 1.81] 0.47 [0.04, 5.69] 0.88 [0.32, 2.41] 1.48 [0.54, 4.03] 1.78 [1.02, 3.11] 1.21 [0.82, 1.78] 5.50 [1.15, 26.32] 2.56 [1.36, 4.85] 1.24 [0.34, 4.52] 1.00 [0.06, 17, 07] 2.95 [1.50, 5.81] 2.59 [1.71, 3.93] 1.21 [0.36, 4.04] 2.10 [0.18, 25.01] 1.57 [0.72, 3.42] 1.49 [0.79, 2.80] 0.81 [0.22, 2.93] 1.00 [0.06, 17, 07]	
est for overall effect: : .1.5 Nausea and von cheng 2019 than(1) 2018 tuang 2019 'u 2019 'u 2018 tuang 2019 'u 2018 tuang 2019 'u 2018 tuang 2019 'u 2018 tetrogeneity: Tau ² = est for overall effect: : .1.6 Hemoptysis tan(1) 2018 tan(2) 2018 tuang 2020 Vang 2020 tobuctal (95% CI) total events teterogeneity: Tau ² = est for overall effect: : .1.7 Pulmonary infect tuang 2020 Vang 2020 Vang 2020 tobu 2019 tubtotal (95% CI) total events tetrogeneity: Tau ² = est for overall effect: 2 .1.8 Dyspnea tuang 2020 tvang 2020 tvang 2020 tvang 2020 tvang 2020 tvang 2020 tvang 2020	Z = 2.43 (P niting 2 13 1 11 12 63 102 0.01; Chi ² = 2 .96 (P 10 60 6 1 1 58 0.00; Chi ² = 2 28 0.00; Chi ² = 2 28 0.00; Chi ² = 2 28 0.00; Chi ² = 1.23 (P 5 1 90	$\begin{array}{c} 25\\ 60\\ 20\\ 33\\ 40\\ 294\\ 472\\ = 5.12, d\\ 472\\ = 5.22\\ 294\\ 351\\ = 0.21, d\\ = 0.221\\ 355\\ 22\\ 294\\ 351\\ = 0.221, d\\ 472\\ = 0.221, d\\ 472$, d\\ 472, d\\ 472,	$\begin{array}{c} 4\\ 15\\ 2\\ 9\\ 9\\ 9\\ 19\\ 61\\ f=5 \ (P=\\ 2\\ 13\\ 5\\ 5\\ 1\\ 11\\ 11\\ 11\\ 11\\ 11\\ 11\\ 11\\ 1$	255 57 20 33 40 143 318 ε 0.40); 57 143 35 22 21 43 400 ε 0.61); 35 22 21 43 200 ε 0.90); 35 22 21 43 200 33 20 20 21 20 21 20 35 22 21 20 33 20 20 33 20 33 20 33 20 20 33 20 33 20 20 20 33 20 20 33 318 20 20 33 20 20 20 33 20 20 20 33 20 20 20 33 20 20 20 20 20 20 20 20 20 20 20 20 20	$\begin{array}{c} 1.9\%\\ 3.7\%\\ 1.3\%\\ 3.3\%\\ 4.3\%\\ 17.8\%\\ 1^2=2\%\\ 2.3\%\\ 4.1\%\\ 2.7\%\\ 1.0\%\\ 14.2\%\\ 1^2=0\%\\ 1^2=0\%\\ 1.3\%\\ 3.8\%\\ 8.0\%\\ 1^2=0\%\\ 1.3\%\\ 3.8\%\\ 8.0\%\\ 1^2=0\%\\ 1.5\%\\ 1.0\%\\ 4.5\%\\ 1.0\%\\ 1.0\%\\ 4.5\%\\ 1.0\%$	0.46 [0.08, 2.75] 0.77 [0.33, 1.81] 0.47 [0.04, 5.69] 0.88 [0.32, 2.41] 1.48 [0.54, 4.03] 1.78 [1.02, 3.11] 1.21 [0.82, 1.78] 5.50 [1.15, 26.32] 2.56 [1.36, 4.85] 1.24 [0.34, 4.52] 1.00 [0.06, 17.07] 2.95 [1.50, 5.81] 2.59 [1.71, 3.93] 1.21 [0.36, 4.04] 2.10 [0.18, 25.01] 1.57 [0.72, 3.42] 1.49 [0.79, 2.80] 0.81 [0.22, 2.93] 1.00 [0.06, 17.07] 1.53 [0.96, 2.44]	
est for overall effect: : .1.5 Nausea and von cheng 2019 Ian(1) 2018 iuang 2019 'u btotal (95% CI) 'otal events teterogeneity: Tau ² = est for overall effect: : .1.6 Hemoptysis tan(1) 2018 tan(2) 2018 tuang 2020 'wang 2020 'chou 2019 'uibtotal (95% CI) 'otal events teterogeneity: Tau ² = est for overall effect: : .1.7 Pulmonary infectuang 2020 'wang 2020 'wang 2020 'wang 2020 'wang 2020 'ang 2020 'ang 2020	Z = 2.43 (P niting 2 13 1 11 12 63 102 0.01; Chi ² = 2 = 0.96 (P 10 60 6 1 2 = 0.96 (P 10 60 6 1 58 135 0.00; Chi ² = 2 2 8 0.00; Chi ² = 2 8 0.00; Chi ² = 2 8 0.00; Chi ² = 2 8 0.00; Chi ² = 2 13 10 5 1.23 (P	$\begin{array}{c} 25\\ 60\\ 20\\ 33\\ 40\\ 294\\ 472\\ = 5.12, d\\ 472\\ = 0.34)\\ 60\\ 294\\ 472\\ 294\\ 472\\ = 0.34)\\ 60\\ 294\\ 35\\ 22\\ 294\\ 705\\ = 2.72, d\\ 35\\ 22\\ 294\\ 351\\ = 0.21)\\ 35\\ 22\\ 294\\ 351\\ \end{array}$	$\begin{array}{c} 4\\ 15\\ 2\\ 9\\ 9\\ 19\\ 19\\ 61\\ 6\\ 1\\ 3\\ 5\\ 1\\ 1\\ 1\\ 1\\ 1\\ 1\\ 1\\ 1\\ 1\\ 1\\ 1\\ 1\\ 1\\$	25 57 20 33 340 143 318 57 7143 35 22 143 400 50 57 143 35 22 143 400 50 50 50 50 50 50 50 50 50 50 50 50 5	1.9% 3.7% 1.3% 3.3% 4.3% 17.8% 1 ² = 2% 2.3% 4.1% 2.7% 1.0% 4.0% 14.2% 1 ² = 0% 2.9% 1.3% 3.8% 8.0% 1 ² = 0%	0.46 [0.08, 2.75] 0.77 [0.33, 1.81] 0.47 [0.04, 5.69] 0.88 [0.32, 2.41] 1.48 [0.54, 4.03] 1.78 [1.02, 3.11] 1.21 [0.82, 1.78] 2.56 [1.36, 4.85] 1.24 [0.34, 4.52] 1.00 [0.06, 17.07] 2.95 [1.50, 5.81] 2.59 [1.71, 3.93] 1.21 [0.36, 4.04] 2.10 [0.18, 25.01] 1.57 [0.72, 3.42] 1.49 [0.79, 2.80] 0.81 [0.22, 2.93] 1.00 [0.06, 17.07] 1.53 [0.92, 2.47]	
est for overall effect: : .1.5 Nausea and von theng 2019 tan(1) 2018 tuang 2019 tu 2019 tu 2019 tu 2018 tuang 2019 tu 2018 tuang 2019 tubtotal (95% CI) total events tan(1) 2018 tuang 2020 thou 2019 tubtotal (95% CI) total events teterogeneity: Tau ² = test for overall effect: : .1.7 Pulmonary infect tuang 2020 thou 2019 tubtotal (95% CI) total events teterogeneity: Tau ² = test for overall effect: : .1.8 Dyspnea tuang 2020 thou 2019 tubtotal (95% CI) total events teterogeneity: Tau ² = test for overall effect: : .1.8 Dyspnea tuang 2020 thou 2019 tubtotal (95% CI) total events teterogeneity: Tau ² = test for overall effect: : .1.8 Dyspnea tuang 2020 thou 2019 tubtotal (95% CI) total events tuang 2020 thou 2019 tubtotal (95% CI) total events tuang 2020 thou 2019 tubtotal (95% CI)	Z = 2.43 (P niting 2 13 1 11 12 63 102 0.01; Chi ² = 0.03; Chi ² = 2 8 0.00; Chi ² = 2 9 0 9 0 9 0 9 0 9 0 0 0 0 0 0 0 0 0 0	$\begin{array}{c} 25\\ 60\\ 20\\ 33\\ 40\\ 294\\ 472\\ =5.12, d\\ 472\\ =0.24, d\\ 351\\ =0.21, d\\ 351\\$	$\begin{array}{c} 4 \\ 15 \\ 2 \\ 12 \\ 9 \\ 9 \\ 19 \\ 19 \\ 61 \\ 61 \\ 1 \\ 11 \\ 1$	255 57 20 33 40 143 318 = 0.40); 57 143 35 22 143 400 = 0.61); 35 22 143 200 = 0.90); 35 22 143 200 = 0.90); 35 22 143 200	$\begin{array}{c} 1.9\%\\ 3.7\%\\ 1.3\%\\ 3.3\%\\ 4.3\%\\ 17.8\%\\ 1^2 = 2\%\\ 2.3\%\\ 4.1\%\\ 2.7\%\\ 1.0\%\\ 4.0\%\\ 14.2\%\\ 1^2 = 0\%\\ 2.9\%\\ 1.3\%\\ 3.8\%\\ 8.0\%\\ 1^2 = 0\%\\ 2.7\%\\ 1.0\%\\ 4.5\%\\ 8.2\%\\ 1.0\%\\ 4.5\%\\ 8.2\%\\ 1.0$	0.46 [0.08, 2.75] 0.77 [0.33, 1.81] 0.47 [0.04, 5.69] 0.88 [0.32, 2.41] 1.48 [0.54, 4.03] 1.78 [1.02, 3.11] 1.21 [0.82, 1.78] 2.56 [1.36, 4.85] 1.24 [0.34, 4.52] 1.00 [0.06, 17, 07] 2.95 [1.50, 5.81] 2.59 [1.71, 3.93] 1.21 [0.36, 4.04] 2.10 [0.18, 25.01] 1.57 [0.72, 3.42] 1.49 [0.79, 2.80] 0.81 [0.22, 2.93] 1.00 [0.06, 17, 07] 1.53 [0.96, 2.44] 1.41 [0.92, 2.17]	
est for overall effect: : .1.5 Nausea and von heng 2019 Ian(1) 2018 Juan(2) 2019 'u 2019 'u 2013 'u 2014 'u 2015 'u 2016 'u 2017 'u 2018 hou 2019 'u 2018 ideterogeneity: Tau ² = est for overall effect: : .1.6 Hemoptysis Ian(2) 2018 tuang 2020 Yang 2020 hou 2019 Uibtotal (95% CI) 'otal events' Idetrogeneity: Tau ² = 'est for overall effect: : .1.7 Pulmonary infect Yang 2020 hou 2019 Vubtotal (95% CI) otal events Idetrogeneity: Tau ² = iest for overall effect: : .1.8 Dyspnea Yang 2020 hou 2019 Vubtotal (95% CI) 'otal events' Idetrogeneity: Tau ² = 'est for overall effect: : 'est for overall effect: </td <td>Z = 2.43 (P niting 2 13 1 11 12 63 102 0.01; Chi² = 0.03; Chi² = 10 60 60 6 1 10 60 6 1 10 60 6 1 1 58 135 0.00; Chi² = 28 0.00; Chi² = 20; Chi² = 20;</td> <td>$\begin{array}{c} 25\\ 60\\ 20\\ 33\\ 40\\ 294\\ 472\\ = 5.12, d\\ 472\\ = 5.12, d\\ 472\\ = 0.34)\\ 60\\ 294\\ 472\\ = 0.34)\\ 60\\ 294\\ 475\\ = 2.72, d\\ 355\\ 22\\ 294\\ 351\\ = 0.21)\\ 355\\ 22\\ 294\\ 351\\ = 0.22)\\ 35\\ 22\\ 294\\ 351\\ = 0.22)\\ 35\\ 22\\ 294\\ 351\\ = 0.20, d\\ = 0.0, d\\ 0 \\ = 0.0, 0, d\\ = 0.0, 0, 0, 0, d\\ = 0.0$</td> <td>$\begin{array}{c} 4\\ 15\\ 2\\ 9\\ 9\\ 19\\ 19\\ 61\\ 6\\ 1\\ 3\\ 5\\ 1\\ 1\\ 1\\ 1\\ 1\\ 1\\ 1\\ 1\\ 1\\ 1\\ 1\\ 1\\ 1\\$</td> <td>255 57 20 33 40 143 318 ε 0.40); 57 143 35 22 143 200 ε 0.61); 35 22 143 200 ε 0.90); 35 22 143 200 ε 0.90); 35 22 143 200 ε 0.90); ε 0.61); 143 200 ε 0.61); 22 21 200 200 200 200 200 200 200 200 2</td> <td>$\begin{array}{c} 1.9\%\\ 3.7\%\\ 1.3\%\\ 3.3\%\\ 4.3\%\\ 17.8\%\\ 1^2=2\%\\ 2.3\%\\ 4.1\%\\ 2.7\%\\ 1.4\%\\ 14.2\%\\ 1^2=0\%\\ 1.3\%\\ 3.8\%\\ 8.0\%\\ 1^2=0\%\\ 1.3\%\\ 3.8\%\\ 8.0\%\\ 1^2=0\%\\ 1.7\%\\ 8.2\%\\ 1^2=0\%\\ 1.0\%\\ 4.5\%\\ 8.2\%\\ 1^2=0\%$</td> <td>0.46 [0.08, 2.75] 0.77 [0.33, 1.81] 0.47 [0.04, 5.69] 0.88 [0.32, 2.41] 1.48 [0.54, 4.03] 1.78 [1.02, 3.11] 1.21 [0.82, 1.78] 2.56 [1.36, 4.85] 1.24 [0.34, 4.52] 1.00 [0.06, 17, 07] 2.95 [1.50, 5.81] 2.59 [1.71, 3.93] 1.21 [0.36, 4.04] 2.10 [0.18, 25.01] 1.57 [0.72, 3.42] 1.49 [0.79, 2.80] 0.81 [0.22, 2.93] 1.00 [0.06, 17, 07] 1.53 [0.96, 2.44] 1.41 [0.92, 2.17]</td> <td></td>	Z = 2.43 (P niting 2 13 1 11 12 63 102 0.01; Chi ² = 0.03; Chi ² = 10 60 60 6 1 10 60 6 1 10 60 6 1 1 58 135 0.00; Chi ² = 28 0.00; Chi ² = 20;	$\begin{array}{c} 25\\ 60\\ 20\\ 33\\ 40\\ 294\\ 472\\ = 5.12, d\\ 472\\ = 5.12, d\\ 472\\ = 0.34)\\ 60\\ 294\\ 472\\ = 0.34)\\ 60\\ 294\\ 475\\ = 2.72, d\\ 355\\ 22\\ 294\\ 351\\ = 0.21)\\ 355\\ 22\\ 294\\ 351\\ = 0.22)\\ 35\\ 22\\ 294\\ 351\\ = 0.22)\\ 35\\ 22\\ 294\\ 351\\ = 0.20, d\\ = 0.0, d\\ 0 \\ = 0.0, 0, d\\ = 0.0, 0, 0, 0, d\\ = 0.0$	$\begin{array}{c} 4\\ 15\\ 2\\ 9\\ 9\\ 19\\ 19\\ 61\\ 6\\ 1\\ 3\\ 5\\ 1\\ 1\\ 1\\ 1\\ 1\\ 1\\ 1\\ 1\\ 1\\ 1\\ 1\\ 1\\ 1\\$	255 57 20 33 40 143 318 ε 0.40); 57 143 35 22 143 200 ε 0.61); 35 22 143 200 ε 0.90); 35 22 143 200 ε 0.90); 35 22 143 200 ε 0.90); ε 0.61); 143 200 ε 0.61); 22 21 200 200 200 200 200 200 200 200 2	$\begin{array}{c} 1.9\%\\ 3.7\%\\ 1.3\%\\ 3.3\%\\ 4.3\%\\ 17.8\%\\ 1^2=2\%\\ 2.3\%\\ 4.1\%\\ 2.7\%\\ 1.4\%\\ 14.2\%\\ 1^2=0\%\\ 1.3\%\\ 3.8\%\\ 8.0\%\\ 1^2=0\%\\ 1.3\%\\ 3.8\%\\ 8.0\%\\ 1^2=0\%\\ 1.7\%\\ 8.2\%\\ 1^2=0\%\\ 1.0\%\\ 4.5\%\\ 8.2\%\\ 1^2=0\%$	0.46 [0.08, 2.75] 0.77 [0.33, 1.81] 0.47 [0.04, 5.69] 0.88 [0.32, 2.41] 1.48 [0.54, 4.03] 1.78 [1.02, 3.11] 1.21 [0.82, 1.78] 2.56 [1.36, 4.85] 1.24 [0.34, 4.52] 1.00 [0.06, 17, 07] 2.95 [1.50, 5.81] 2.59 [1.71, 3.93] 1.21 [0.36, 4.04] 2.10 [0.18, 25.01] 1.57 [0.72, 3.42] 1.49 [0.79, 2.80] 0.81 [0.22, 2.93] 1.00 [0.06, 17, 07] 1.53 [0.96, 2.44] 1.41 [0.92, 2.17]	
Fest for overall effect: : 2.1.5 Nausea and von Cheng 2019 tan(1) 2018 tuang 2019 fue 2018 for 2019 fue 2018 for 2019 fue 2018 for 2019 Subtotal (95% CI) fotal events feterogeneity: Tau ² = fest for overall effect: : 2.1.6 Hemoptysis tan(1) 2018 tan(2) 2018 tan(2) 2018 tau(2) 2018 tau(2) 2018 tau(2) 2018 tear(2) 2018 tear(2) 2019 Subtotal (95% CI) fotal events feterogeneity: Tau ² = fest for overall effect: : 2.1.7 Pulmonary infect fuang 2020 Yang 2020 fotal events feterogeneity: Tau ² = fest for overall effect: : 2.1.8 Dyspnea fuang 2020 Yang 2020 Yang 2020 Yang 2020 Yang 2020	Z = 2.43 (P niting 2 13 1 1 12 63 102 0.01; Chi ² = 0.02; Chi ² = 2 8 0.00; Chi ² = 2 8 0.00; Chi ² = 2 8 0.00; Chi ² = 1.23 (P 5 1 90 96 0.00; Chi ² = 1.56 (P	$\begin{array}{c} 25\\ 60\\ 20\\ 33\\ 40\\ 294\\ 472\\ = 5.12, d\\ 472\\ = 5.12, d\\ 472\\ = 5.12, d\\ 472\\ = 5.12, d\\ 472\\ = 2.24\\ 705\\ = 2.72, d\\ 355\\ = 2.72, d\\ 351\\ = 0.221, d\\ 351\\ = 0.221, d\\ 351\\ = 0.221, d\\ 351\\ = 0.90, d\\ 351\\ = 0.90, d\\ = 0.12\\ \end{array}$	$\begin{array}{c} 4\\ 15\\ 2\\ 9\\ 9\\ 19\\ 61\\ f=5 \ (P=\\ 2\\ 13\\ 5\\ 1\\ 11\\ 11\\ 11\\ f=4 \ (P=\\ 01)\\ 01\\ 0\\ 1\\ 9\\ 16\\ f=2 \ (P=\\ 2\\ (P=\\$	255 57 20 33 318 $\in 0.40);$ 57 143 35 22 143 400 $\in 0.61);$ 35 22 143 200 $\in 0.90);$ 35 22 143 200 $\in 0.90);$ 35 22 143 200 $\in 0.90);$ 35 22 2 143 200 = 0.00);	$\begin{array}{c} 1.9\%\\ 3.7\%\\ 1.3\%\\ 3.3\%\\ 4.3\%\\ 17.8\%\\ 1^2=2\%\\ 2.3\%\\ 4.1\%\\ 2.7\%\\ 1.0\%\\ 14.2\%\\ 1^2=0\%\\ 1^2=0\%\\ 1.3\%\\ 3.8\%\\ 8.0\%\\ 1^2=0\%\\ 1.3\%\\ 3.8\%\\ 8.0\%\\ 1^2=0\%\\ 1.0\%\\ 4.5\%\\ 8.2\%\\ 1^2=0\%$	0.46 [0.08, 2.75] 0.77 [0.33, 1.81] 0.47 [0.04, 5.69] 0.88 [0.32, 2.41] 1.48 [0.54, 4.03] 1.78 [1.02, 3.11] 1.21 [0.82, 1.78] 2.56 [1.36, 4.85] 1.24 [0.34, 4.52] 1.00 [0.06, 17,07] 2.95 [1.50, 5.81] 2.59 [1.71, 3.93] 1.21 [0.36, 4.04] 2.10 [0.48, 25.01] 1.57 [0.72, 3.42] 1.49 [0.79, 2.80] 0.81 [0.22, 2.93] 1.00 [0.06, 17.07] 1.53 [0.96, 2.44] 1.41 [0.92, 2.17]	
Test for overall effect: : 2.1.5 Nausea and von Cheng 2019 tan(1) 2018 tuang 2019 (ua 2019) (ua 2019) (ua 2019) (ua 2019) (ua 2019) Subtotal (95% CI) Folal events teterogeneity: Tau ² = est for overall effect: : 2.1.6 Hemoptysis tan(1) 2018 tuang 2020 Vang 2020 Yang 202	Z = 2.43 (P niting $2 = 3.43 (P) = 1.56 (P)$ $Z = 0.96 (P) = 10$ $10 = 0.01; Chi2 = 2.83$ $1.02 = 0.96 (P) = 10$ $60 = 6$ $10 = 60$ $61 = 1.58$ $1.02 = 0.96 (P) = 1.23 (P)$ $5 = 1.23 (P) = 5$ $1 = 1.23 (P) = 5$ $1 = 1.23 (P) = 5$ $2 = 1.26 (P) = 1.25 (P)$		$\begin{array}{c} 4\\ 15\\ 2\\ 9\\ 9\\ 19\\ 61\\ f=5 \ (P=\\ 2\\ 13\\ 5\\ 1\\ 11\\ 11\\ 11\\ 11\\ f=4 \ (P=\\ 01)\\ 6\\ 1\\ 9\\ 16\\ f=2 \ (P=\\ 2\\ (P=\\ 39\\ g=2 \ (P=\\ 12\\ 12\\ 12\\ 12\\ 12\\ 12\\ 12\\ 12\\ 12\\ 12$	25 57 20 33 40 143 318 57 143 35 22 143 400 e 0.40); 35 22 2143 200 e 0.90); 35 22 2143 200 e 0.64); 2431	1.9% 3.7% 1.3% 3.3% 4.3% 17.8% 1 ² = 2% 2.3% 4.1% 2.7% 1.0% 4.0% 14.2% 1 ² = 0% 2.9% 1.3% 3.8% 1.3% 3.8% 1.2% 1 ² = 0% 1.0% 4.5% 6.2% 1 ² = 0%	0.46 [0.08, 2.75] 0.77 [0.33, 1.81] 0.47 [0.04, 5.69] 0.88 [0.32, 2.41] 1.48 [0.54, 4.03] 1.78 [1.02, 3.11] 1.21 [0.82, 1.78] 2.56 [1.36, 4.85] 1.24 [0.34, 4.52] 1.00 [0.06, 17.07] 2.95 [1.50, 5.81] 2.59 [1.71, 3.93] 1.21 [0.36, 4.04] 2.10 [0.18, 25.01] 1.57 [0.72, 3.42] 1.49 [0.79, 2.80] 0.81 [0.22, 2.93] 1.00 [0.06, 17.07] 1.53 [0.96, 2.44] 1.41 [0.92, 2.17]	
Test for overall effect: : .1.5 Nausea and von >heng 2019 tan(1) 2018 tuang 2019 'u 2019 'u 2019 'u 20119 'u 2013 'u 2014 bubtotal (95% Cl) 'oial events teterogeneity: Tau ² = 'est for overall effect: : 1.6 Hemoptysis tan(1) 2018 tuang 2020 Yang 2020 You 2018 tuang 2020 Yang 2020 'hou 2019 ubtotal (95% Cl) 'oial events teterogeneity: Tau ² = 'est for overall effect: : .1.7 Pulmonary infectuang 2020 'hou 2019 ubtotal (95% Cl) 'oial events teterogeneity: Tau ² = 'est for overall effect: : .1.8 Dyspnea ubtotal (95% Cl) 'oial events teterogeneity: Tau ² = 'est for overall effect: : 'oial events teterogeneity: Tau ² =	Z = 2.43 (P niting 2 13 1 11 12 63 102 0.01; Chi ² = 0.96 (P 10 60 6 1 135 0.00; Chi ² = 28 37 0.00; Chi ² = 28 37 190 200; Chi ² = 28 21,23 2		$\begin{array}{c} 4\\ 15\\ 2\\ 9\\ 9\\ 19\\ 61\\ 6\\ 13\\ 5\\ 1\\ 1\\ 11\\ 32\\ 6\\ 16\\ 1\\ 9\\ 9\\ 16\\ 6\\ 1\\ 32\\ 39\\ 9\\ f=2\ (P=3)\\ 338\\ 8\\ 338\\ 8\\ 388\\ 388\\ 388\\ 388\\ $	255 57 20 33 340 143 318 57 143 35 22 143 200 5 5 22 143 200 5 5 22 143 200 5 5 22 143 200 5 5 22 143 200 5 5 22 143 200 5 22 143 200 20 20 20 20 20 20 20 20 20 20 20 20	1.9% 3.7% 1.3% 3.3% 4.3% 17.8% 1 ² = 2% 2.3% 4.1% 2.7% 1.0% 4.0% 14.2% 1 ² = 0% 2.9% 1.3% 3.8% 8.0% 1 ² = 0% 1.0% 4.5% 8.2% 1 ² = 0%	0.46 [0.08, 2.75] 0.77 [0.33, 1.81] 0.47 [0.04, 5.69] 0.88 [0.32, 2.41] 1.48 [0.54, 4.03] 1.78 [1.02, 3.11] 1.21 [0.82, 1.78] 2.56 [1.36, 4.85] 1.24 [0.34, 4.52] 1.00 [0.06, 17, 07] 2.95 [1.50, 5.81] 2.59 [1.71, 3.93] 1.21 [0.36, 4.04] 2.10 [0.18, 25.01] 1.57 [0.72, 3.42] 1.49 [0.79, 2.80] 0.81 [0.22, 2.93] 1.00 [0.06, 17.07] 1.53 [0.96, 2.44] 1.41 [0.92, 2.17]	
est for overall effect: : 1.5 Nausea and von heng 2019 an(1) 2018 uang 2019 u 2018 hou 2019 u 2018 hou 2019 ubtotal (95% CI) otal events eterogeneity: Tau ² = : est for overall effect: : 1.6 Hemoptysis an(1) 2018 an(2) 2018 uang 2020 /ang 2020 /	Z = 2.43 (P niting 2 13 1 1 11 2 63 102 0.01; Chi ² = 0.00; Chi ² = 2 8 0.00; Chi ² = 2 8 0.00; Chi ² = 2 8 0.00; Chi ² = 1.23 (P 5 1 90 96 0.00; Chi ² = 1.56 (P 1218 0.55; Chi ² =	$\begin{array}{c} 25\\ 60\\ 20\\ 33\\ 40\\ 294\\ 472\\ = 5.12, d\\ 472\\ = 5.12, d\\ 472\\ = 5.12, d\\ 472\\ = 5.12, d\\ 472\\ = -0.34\\ 705\\ = 2.22\\ 294\\ 351\\ = 0.22\\ 294\\ 351\\ = 0.22\\ 294\\ 351\\ = 0.92, d\\ 351\\ = 0.9$	$\begin{array}{c} 4\\ 15\\ 2\\ 9\\ 9\\ 9\\ 9\\ 19\\ 61\\ f=5 \ (P=\\ 2\\ 13\\ 5\\ 1\\ 11\\ 11\\ 11\\ 11\\ 11\\ 11\\ 11\\ 11\\ $	25 57 20 33 40 143 318 318 318 318 318 32 22 143 20 0 = 0.61); 35 22 143 200 = 0.90); 35 52 22 143 200 = 0.90); 2431 (P < 0.	1.9% 3.7% 1.3% 3.3% 4.3% 17.8% 1 ² = 2% 2.3% 4.1% 2.7% 1.0% 4.0% 14.2% 1 ² = 0% 2.9% 1.3% 3.8% 8.0% 1 ² = 0% 2.7% 1.0% 4.5% 8.2% 1 ² = 0% 100.0%	0.46 [0.08, 2.75] 0.77 [0.33, 1.81] 0.47 [0.04, 5.69] 0.88 [0.32, 2.41] 1.48 [0.54, 4.03] 1.78 [1.02, 3.11] 1.21 [0.82, 1.78] 5.50 [1.15, 26.32] 2.56 [1.36, 4.85] 1.24 [0.34, 4.52] 1.00 [0.06, 17.07] 2.95 [1.57, 5.81] 2.59 [1.71, 3.93] 1.21 [0.36, 4.04] 2.10 [0.48, 25.01] 1.57 [0.72, 3.42] 1.57 [0.72, 3.42] 1.49 [0.79, 2.80] 0.81 [0.22, 2.93] 1.00 [0.06, 17.07] 1.53 [0.96, 2.44] 1.41 [0.92, 2.17] 1.97 [1.43, 2.72] = 74%	

Figure 9. Forest plot of the treatment related adverse event between experimental group and control group.



4.3. Limitations

The limitations of this study should be noted. First of all, the quality of the included trials were not high enough according to the Jada scores and risk of bias analysis. Second, the time to market is too short for researchers to carry out enough large-scale trials. The on-going or completed studies are mostly performed in China which may be limited of global reference value. Third, we did not perform subgroup analysis of survival factors such as age, pathological types, KPS score, EGFR mutation and so on, which need to be further explored.

5. Conclusion

Our study suggested that, anlotinib, as maintenance therapy for advanced NSCLC patients is associated with significantly prolonged PFS and OS as well as DCR improvement, but accompanied by increased risk of TRAE, such as hypertension, hepatic dysfunction, diarrhea and hemoptysis. Although much effort has been made for the clinical trials of anlotinib, existing limitations require further studies to provide more convincing clinical evidence.

Acknowledgments

It was acknowledged that these 3 authors of Haiyong Ye, Zhaoyi Li and Kangning Liu contributed equally to this work, to be regarded as the co-authors.

Author contributions

Conceptualization: Haiyong Ye, Zhengliang Cheng. Data curation: Haiyong Ye, Zhaoyi Li, Kangning Liu. Formal analysis: Haiyong Ye, Zhaoyi Li, Kangning Liu. Funding acquisition: Haiyong Ye, Kangning Liu, Zhengliang Cheng.

- Investigation: Haiyong Ye, Zhaoyi Li.
- Methodology: Haiyong Ye, Zhaoyi Li, Kangning Liu.
- Software: Haiyong Ye, Zhaoyi Li, Kangning Liu.
- Supervision: Haiyong Ye, Zhaoyi Li, Kangning Liu, Zhengliang Cheng, Feng Zhang.
- Validation: Zhengliang Cheng.
- Visualization: Zhaoyi Li, Kangning Liu.
- Writing original draft: Haiyong Ye, Zhaoyi Li, Kangning Liu.
- Writing review & editing: Haiyong Ye, Zhaoyi Li, Kangning Liu, Zhengliang Cheng, Feng Zhang.

References

- Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBO-CAN 2012. Int J Cancer 2015;136:E359–86.
- [2] Fitzmaurice C, Abate D, et al. Global Burden of Disease Cancer CollaborationGlobal, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted lifeyears for 29 cancer groups, 1990 to 2017: a systematic analysis for the Global Burden of Disease Study. JAMA Oncol 2019;5:1749–68.
- [3] Iacono D, Chiari R, Metro G, et al. Future options for ALK-positive nonsmall cell lung cancer. Lung Cancer 2015;87:211–9.
- [4] Blandin Knight S, Crosbie PA, Balata H, et al. Progress and prospects of early detection in lung cancer. Open Biol 2017;7:170070doi: 10.1098/ rsob.170070. PMID: 28878044; PMCID: PMC5627048.
- [5] Wang N, Mengersen K, Tong S, et al. Global, regional, and national burden of lung cancer and its attributable risk factors, 1990 to 2017 published online ahead of print, 2020 Jul 10. Cancer 2020;10:1002/ cncr.33078doi:10.1002/cncr.33078.
- [6] Li J, Yang F, Li X, et al. Characteristics, survival, and risk factors of Chinese young lung cancer patients: the experience from two institutions. XXXX 2017;8:89236–44.

- [7] Kim SY, Halmos B. Choosing the best first-line therapy: NSCLC with no actionable oncogenic driver. Lung Cancer Manag 2020; 9:LMT36doi: 10.2217/lmt-2020-0003. PMID: 32774467; PMCID: PMC7399613.
- [8] Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543–51.
- [9] García-González J, Ruiz-Bañobre J, Afonso-Afonso FJ, et al. PD-(L)1 inhibitors in combination with chemotherapy as first-line treatment for non-small-cell lung cancer: a pairwise meta-analysis. J Clin Med 2020;9: E2093Published 2020 Jul 3. doi:10.3390/jcm9072093.
- [10] Rebuzzi SE, Alfieri R, La Monica S, et al. Combination of EGFR-TKIs and chemotherapy in advanced EGFR mutated NSCLC: Review of the literature and future perspectives. Crit Rev Oncol Hematol 2020;146:102820doi: 10.1016/j.critrevonc.2019.102820. Epub 2019 Oct 31. PMID: 31785991.
- [11] Qiang H, Chang Q, Xu J, et al. New advances in antiangiogenic combination therapeutic strategies for advanced non-small cell lung cancer. J Cancer Res Clin Oncol 2020;146:631–45.
- [12] Zhou M, Chen X, Zhang H, et al. China National Medical Products Administration approval summary: anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy. Cancer Commun (Lond) 2019;39:36Published 2019 Jun 20. doi:10.1186/s40880-019-0383-7.
- [13] J. P. T. Higgins and S. Green, Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0, The Cochrane Collaboration, 2012, http://handbook.cochrane.org.
- [14] Han B, Li K, Zhao Y, et al. Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302). Br J Cancer 2018;118:654–61.
- [15] Han B, Li K, Wang Q, et al. Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non-small cell lung cancer: the ALTER 0303 phase 3 randomized clinical trial published correction appears in JAMA Oncol. 2018 Nov 1;4(11):1625. JAMA Oncol 2018;4:1569–75. doi:10.1001/jamaoncol.2018.3039.
- [16] Cheng Y, Wang Q, Li K, et al. Anlotinib as third-line or further-line treatment in relapsed SCLC: a multicentre, randomized, double-blind phase 2 trial: OA13. 03. J Thoracic Oncol 2018;1310:
- [17] Yue K. Study on the value of anlotinib capsule combined with cisplatin in the treatment of non-small cell lung cancer with malignant pleural effusion. Exploration Rational Drug China 2018;15:84–6. +93.
- [18] Cheng Y, Wang Q, Li K, et al. Overall survival (OS) update in ALTER 1202: anlotinib as third-line or further-line treatment in relapsed smallcell lung cancer (SCLC). Ann Oncol 2019;30:v711.

- [19] Dai X, Zhang Y, Han L, et al. The clinical effect of anlotinib in the treatment of advanced non-small cell lung cancer. China Med Herald 2019;16:95–8.
- [20] Yu S, Yang S, Wang H, et al. Efficacy and safety analysis of anlotinib combined with docetaxel in the second-line treatment of advanced lung adenocarcinoma. Contemporary Med 2019;25:131–2.
- [21] Zhang K, Zhang M, Zhang T. Analysis of therapeutic efficacy and adverse reactions of anlotinib in EP regimen-resistant small-cell lung cancer. China Med Sci 2019;9:58–60+115.
- [22] Huang X, Cai F, Liu G, et al. Clinical analysis of anlotinib combined with radiotherapy in the treatment of non-small cell lung cancer with brain metastasis. Primary Med Forum 2020;24:5–7.
- [23] Jiang S, Liang H, Liu Z, et al. The impact of anlotinib on brain metastases of non-small cell lung cancer: post hoc analysis of a phase III randomized control trial (ALTER0303). Oncologist 2020;25:e870.
- [24] Huang F, Li W, Zhang H, et al. Effects of an lotinib capsule in the treatment of advanced non-small cell lung cancer on VEGF levels and survival time. Practical J Cancer 2020;35:360–2.
- [25] Wang C, et al. The effectiveness of anlotinib capsules in the treatment of advanced non-small cell lung cancer. Chinese Health Standard Management 2020;11:75–6.
- [26] Shen G, Zheng F, Ren D, et al. Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development. J Hematol Oncol 2018;11:120Published 2018 Sep 19. doi:10.1186/s13045-018-0664-7.
- [27] Yang S, Zhang Z, Wang Q. Emerging therapies for small cell lung cancer. J Hematol Oncol 2019;12:47Published 2019 May 2. doi:10.1186/ s13045-019-0736-3.
- [28] Sun Y, Niu W, Du F, et al. Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors. J Hematol Oncol 2016;9:105Published 2016 Oct 4. doi:10.1186/s13045-016-0332-8.
- [29] Lin B, Song X, Yang D, et al. Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFRβ and FGFR1 published correction appears in Gene. 2020 Jan 10;723:144119. Gene 2018;654:77–86.
- [30] Zhong CC, Chen F, Yang JL, et al. Pharmacokinetics and disposition of anlotinib, an oral tyrosine kinase inhibitor, in experimental animal species. Acta Pharmacol Sin 2018;39:1048–63.
- [31] Shah RR, Morganroth J, Shah DR. Hepatotoxcity of tyrosine kinase inhibitors: clinical and regulatory perspectives. Drug Saf 2013;36:491– 503.
- [32] Spraggs CF, Xu CF, Hunt CM. Genetic characterization to improve interpretation and clinical management of hepatotoxcity caused by tyrosine kinase inhibitors. Pharmacogenomics 2013;14:541–54.